Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Hygiene hypothesis wikipedia , lookup
Epidemiology wikipedia , lookup
Forensic epidemiology wikipedia , lookup
Eradication of infectious diseases wikipedia , lookup
Compartmental models in epidemiology wikipedia , lookup
Public health genomics wikipedia , lookup
Prenatal testing wikipedia , lookup
Focal infection theory wikipedia , lookup
Activity test of Commiphora myrrh to Helicobacter pylori compared with commonly used Antimicrobial Agents Thesis Submitted by Huda Mohamed El Mahdi Salih B. Sc 2000 Sudan university For degree of master of microbiology Under supervision of Prof. Elshiekh Ali Elebiad Department of microbaiology Faculty of pharmacy University of Khartoum 2008 ﻗﺎل ﺗﻌﺎﻟﻰ : ﺑﺴﻢ اﷲ اﻟﺮﺣﻤﻦ اﻟﺮﺣﻴﻢ ﻼ( ﻻ َﻗﻠِﻴ ً ) َوﻣَﺎ أُوﺗِﻴﺘُﻢ ﻣﱢﻦ ا ْﻟ ِﻌ ْﻠ ِﻢ ِإ ﱠ ﺻﺪق اﷲ اﻟﻌﻈﻴﻢ اﻹﺳﺮاء اﻵﻳﺔ) ( 85 I Dedication To Soul of my Father and grand father To my mother and my Family To my sister Hwaida who spared no effort to help me To my husband & my lovely Kids Hosham & Aymn To all whom I love II Acknowledgment I wish to express my special appreciation and sincere gratitude to Prof. Elshei kh Ali Elobaid for close supervision and continuous moral support. My thanks also to my co –supervisor Dr. Elamin Ibrahim Elnema for his kind help . Also special thanks to Dr. Hekma Yousif Mohamed Elzin for her continuous support . I also extend my warmest thanks to my colleagues at N.H.L for their continuous support Also I would like to extended my thanks to the staff of endoscopy department and staff of laboratory of Ibn Sinna Hospital and specially to Abd Elrazig Hammad Suleiman I would like to thank Dr. Amira Mahjoub Mycoplasma Dept. Central Veterinary Research laboratories Center Soba Mr. Awad Elsead Abd Elgbar Mycoplasma Dept. Central Veterinary Research laboratories Center Soba N.H.l.. bacteriology department members and growth media unit The epidemiology department members manly Mohamed abd Elrahman and Vaccine department members at N.H.L Mr Ali M. Nor Eldein. Laboratory Administration Khartoum State Dr. Eldoma H. Adil N.H.LVirology department Miss Kawthar Abdelgaleil Mohamed Salih N.H.L. Immunology & Allergy department Sarah Elsarag & Salah Elrwa my friend & colleague whom I sheered the hardest day Mr. Malik Abd Allah N.H.L. and Mrs. Suzan Fathi I am extremely grateful for support & advice and cooperation from my lovely famil III Abbreviations CagA CD IgG IgM IL8 BHI CFU IgA HpSA H. pylori H. bizzozeronii STAT LPS PCR RNA UBT VacA NF.B PUD PPI ELISA ZES MALT NSAID Am Tet Cla Met RBC Clo Pu DU GU cytotoxin associated gene A cluster of differentiation immunoglobulin G immunoglobulin M interleukin8 Brain heart infusion colony forming units immunoglobulin A Helicobacter pylori stool antgen Helicobacter pylori Helicobacter bizzozeronii signal transducer and activator of transcription lipopolysaccharide polymerase chain reaction ribonucleic acid Urea breath test Vacuolating cytotoxin A Nuclear factor B Peptic ulcer disease proton pump inhibitor enzyme linked immunosorbant assay Zollinger-Ellison syndrome mucosa associated lymphatic tissue Non steroidal anti-inflammatory Amoxicilin tetracycline Clarithromicin Metronidazole ranitidine bismuth citrate Campylobacter-like organism test peptic ulcer duodenum ulcer gastric ulcer IV Abstract The present study aimed to isolate Helicobacter pylori and conduct the susceptibility tests to Commiphora myrrh in comparison with widely used antibiotics. The study samples were collected from Sudanese patients who were suffering from peptic disease during the period September 2006 to November 2007 in Ibn Sina T. Hospital. The study population was 52 females and 48 males their ages ranged between 19 and 70 years. It was observed that high prevalence of Helicobacter pylori infection in old ages . The study included 32 manual worker, 31 house wives and 15 students , 6 farmers and 16 other jobs (Doctors ,Employers ,Engineers and Teachers). Helicobacter pylori was isolated in sixty of the total of one hundred specimen collected. The sensitivity tests were done against Amoxicillin, tetracycline ,Metronidazole and Clarithromycin by disk diffusion method and Commiphora myrrh extraction by agar dilution in four dilution 1/20,1/40,1//80 and 1/160. It was found that 71% of isolates were sensitive to Amoxicillin, 61.7%Tetracycline ,38.3% to Metronedazole and35% to Clarithromicin ,In Commiphora myrrh dilution one (1/20)which highist sensitivity rate 100% . Dilution two(1/40) 90% .50% for dilution three(1/80). And 20 % for dilution four (1/160) . That means that Amoxicillin is the best choice and the MIC of Commiphora myrrh extraction is 1/20 and Commiphora myrrh may be examined as an alternative treatment against Helicobacter pylori . V ﺒﺴﻡ ﺍﷲ ﺍﻟﺭﺤﻤﻥ ﺍﻟﺭﺤﻴﻡ ﻤﺴﺘﺨﻠﺹ ﺍﻷﻁﺭﻭﺤﺔ ﻫﺩﻓﺕ ﺍﻟﺩﺭﺍﺴﺔ ﺍﻟﺤﺎﻟﻴﺔ ﻟﻌﺯل ﻤﻴﻜﺭﻭﺏ) ﺍﻟﻬﻴﻠﻜﻭﺒﺎﻜﺘﺭ ﺒﻴﻠﻭﺭﻯ( ﻭﺩﺭﺍﺴﺔ ﺩﺭﺠﺔ ﺤﺴﺎﺴﻴﺘﻬﺎ ) ﻟﻤﺭ ﻫﺎﺭﺒـل( ﻤـﺎ ﻴﻌﺭﻑ ﻓﻰ ﺍﻟﺴﻭﺩﺍﻥ ﺒﺎﻟﻤﺭ ﺍﻟﺤﺠﺎﺯﻯ ﻤﻘﺎﺭﻨﺔ ﺒﺎﻟﻤﻀﺎﺩﺍﺕ ﺍﻟﺤﻴﻭﻴﺔ ﺍﻻﻜﺜﺭ ﺍﺴﺘﺨﺩﺍﻤﺎ ﻓﻰ ﺍﻟﻌﺎﻟﻡ. ﺃﺠﺭﻴﺕ ﺍﻟﺩﺭﺍﺴﺔ ﻋﻠﻰ ﻋﻴﻨﺎﺕ ﺍﻨﺴﺠﺔ ﻤﻥ ﻤﺭﻀﻰ ﺴﻭﺩﺍﻨﻴﻴﻥ ﻴﻌﺎﻨﻭﻥ ﻤﻥ ﺍﻟﻘﺭﺤﺔ ﺍﻟﻤﻌﺩﻴﺔ ﺨـﻼل ﺍﻟﻔﺘـﺭﺓ ﻤـﻥ ﺴﺒﺘﻤﺒﺭ 2006ﺍﻟﻰ ﻨﻭﻓﻤﺒﺭ 2007ﺒﻤﺴﺘﺸﻔﻰ ﺍﺒﻥ ﺴﻴﻨﺎ ﻗﺴﻡ ﺍﻟﻤﻨﺎﻅﻴﺭ . ﺸﻤﻠﺕ ﺍﻟﺩﺭﺍﺴﺔ 52ﻤﻥ ﺍﻻﻨﺎﺙ ﻭ 48ﻤﻥ ﺍﻟﺭﺠﺎل ﺘﺘﺭﺍﻭﺡ ﺍﻋﻤﺎﺭﻫﻡ ﺒﻴﻥ 19ﺍﻟﻰ 70ﺴﻨﺔ ﻭﻭﺠـﺩﺕ ﺍﻻﺼـﺎﺒﺔ ﺒﺎﻟﻬﻴﻠﻭﻜﻭﺒﺎﻜﺘﺭ ﺒﻴﻠﻭﺭﻯ ﺍﻜﺜﺭ ﺸﻴﻭﻋﺎ ﻓﻰ ﺍﻻﻋﻤﺎﺭ ﺍﻻﻜﺒﺭ . ﻭﺸﻤﻠﺕ ﺍﻟﺩﺭﺍﺴﺔ 32ﻤﻥ ﺍﺼﺤﺎﺏ ﺍﻻﻋﻤﺎل ﺍﻟﺤﺭﺓ ﻭ 31ﻤﻥ ﺭﺒﺎﺕ ﺍﻟﺒﻴﻭﺕ 15ﻤﻥ ﺍﻟﺘﻼﻤﻴﺫ ﻭ 6ﻤﺯﺍﺭﻋﻴﻥ ﻭ16 ﻤﻥ ﺍﻟﻤﻬﻥ ﺍﻻﺨﺭﻯ ) ﺍﻁﺒﺎﺀ ﻤﻬﻨﺩﺴﻴﻥ ﻭﻤﺤﺎﻤﻴﻴﻥ ﻭ ﻤﻌﻠﻤﻴﻥ ( ﻋﺯﻟﺕ ﺒﻜﺘﺭﻴﺎ ﺍﻟﻬﻠﻜﻭﺒﺎﻜﺘﺭ ﺒﻴﻠﻭﺭﻯ ﻤﻥ ﺴﺘﻴﻥ ﻋﻴﻨﺔ ﻤﻥ ﻤﺠﻤﻭﻉ ﻤﺎﺌﺔ ﻭﺍﺠﺭﻱ ﻟﻬﺎ ﺍﺨﺘﺒﺎﺭ ﺍﻟﺤﺴﺎﺴﻴﺔ ﻟﻠﻤﻀﺎﺩﺍﺕ ﺍﻟﺤﻴﻭﻴﺔ )ﺍﻤﻭﻜﺴﺴﻠﻴﻥ ﻭﺘﺘﺭﺍﺴﻴﻜﻠﻴﻥ ﻭﻜﻼﺭﻴﺜﺭﻭﻤﺎﻴﺴﻥ ﻭﻤﻴﺘﺭﻭﻨﻴﺩﺍﺯﻭل (ﺒﻁﺭﻴﻘﺔ ﺍﻨﺘﺸﺎﺭ ﺍﻻﻗﺭﺍﺹ ﺍﻟﻤـﺸﺭﺒﺔ ﻭﻟﻠﻤـﺭ ﺍﻟﺤﺠﺎﺯﻯ ﺒﻁﺭﻴﻘﺔ ﺘﺨﻔﻴﻑ ﺍﻻﻗﺎﺭ ﺒﺎﻟﺘﺨﻔﻴﻑ ﺍﻟﻤﻀﺎﻋﻑ 20/1ﻭ 40/1ﻭ 80/1ﻭ 160/1ﻭﻭﺠﺩ ﺍﻥ ﻨـﺴﺒﺔ ﺍﻟﺘﺤـﺴﺱ ﻟﻼﻤﻭﻜﺴﺴﻠﻴﻥ %71ﻭﻟﻠﺘﺘﺭﺍﺴﻴﻜﻠﻴﻥ %61ﻭﻟﻠﻤﻴﺘﺭﻭﻨﻴﺩﺍﺯﻭل %38.3ﻭ %35ﻟﻠﻜﻼﺭﻴﺜﺭﻭﻤﺎﻴـﺴﻥ ﻭﺒﺎﻟﻨـﺴﺒﺔ ﻟﻠﻤـﺭ ﺍﻟﺤﺠﺎﺯﻯ ﺍﻋﻁﻰ ﺘﺤﺴﺱ ﻋﺎﻟﻰ ﺒﻨﺴﺒﺔ %100ﻓﻰ ﺍﻟﺘﺤﻔﻴﻑ ﺍﻻﻭل ) (20/1ﻭ %90ﻟﻠﺘﺤﻔﻴﻑ ﺍﻟﺜﺎﻨﻰ) (40/1ﻭ%50 ﻟﻠﺘﺨﻔﻴﻑ ﺍﻟﺜﺎﻟﺙ ) (80/1ﻭﻜﺎﻨﺕ ﻨﺴﺒﺔ ﺍﻟﺘﺤﺴﺱ ﻓﻲ ﺍﻟﺘﺨﻔﻴﻑ ﺍﻟﺭﺍﺒﻊ ﻭﺍﻻﺨﻴﺭ )%20 (160/1 ﻫﺫﺍ ﻴﻌﻨﻰ ﺍﻥ ﺍﻻﻤﻭﻜﺴﺴﻠﻴﻥ ﻭﺍﻟﺘﺘﺭﺍﺴﻴﻜﻠﻴﻥ ﻫﻤﺎ ﺍﻟﺨﻴﺎﺭﻴﻥ ﺍﻻﻓﻀﻠﻴﻥ .ﻭﺍﻥ ﺍﻗل ﺘﺭﻜﻴﺯ ﻟﻠﻤﺭ ﺍﻟﺤﺠـﺎﺯﻯ ﺍﻟـﺫﻯ ﻴﺜﺒﻁ ﻨﻤﻭ ﺍﻟﺒﻜﺘﺭﻴﺎ ﻫﻭ ،20/1ﻜﻤﺎ ﺍﻨﻪ ﻴﻌﻨﻰ ﺍﻥ ﺍﻟﻤﺭ ﺍﻟﺤﺠﺎﺯﻯ ﻴﻤﻜﻥ ﺍﻥ ﻴﺨﺘﺒﺭ ﻜﻌﻼﺝ ﺒﺩﻴل ﻀـﺩ ) ﺍﻟﻬﻠﻜﻭﺒـﺎﻜﺘﺭ ﺒﻴﻠﻭﺭﻱ(. VI Table of content Title Page No. Verse I Dedication II Acknowledgment III Abbreviations IV Abstract in English V Abstract in Arabic VI Chapter One Introduction and Literature review Peptic Ulcer 1 1 Causes of peptic ulcer 2 Symptoms of peptic ulcer 4 Other symptoms 4 Emergency Symptoms 4 Treatment of peptic ulcer : 5 Helicobacter 5 Characteristic 6 Habitat 6 Species 6 Antigenic structures 7 culture and colony morphology 7 Pathogenesis 8 Diseases 9 Diagnosing 10 VII Histology 10 Culture 11 Rapid urease test 11 Urease breath test 12 Serology 12 Stool antigen test 13 Near patient test 14 Salivary and urine antibody 14 Molecular test 14 String test 15 Immunity 15 Transmission 15 Epidemiology 16 Treatment 16 First-line treatment 16 Second-line therapies 18 Resistance 18 Medical plants 19 The activity of medical plants 19 Commiphora myrrh 20 Active Compounds 22 Objective of the study 23 Chapter Two Materials and methods 24 Study approach 24 Study design 24 VIII Study area 24 Study variables 24 Study population 24 Selection criteria 24 Ethical clearance 24 Material 24 Methods 26 Collection of the samples 26 Rapid urease test 26 Culture 26 Identification of the isolate: 27 Colonial morphology 27 Gram stain 27 Urease test 27 Catalase test 28 Oxidase test 28 Sensitivity test 28 Inoculums’ preparation 28 Disk diffusion methods 29 Disc diffusion method of antimicrobial 29 Agar dilution method 29 data analysis 30 Chapter Three Result 31 Demographic features of study population 31 Gender And Age 31 IX Residence distribution 31 Occupation distribution 31 Endoscopy result 31 Rapid urease test result 31 Culture result 32 Sensitivity test result: 32 Antibiotic desk result 32 Plant antimicrobial result 32 Chapter Four Discussion 53 Chapter Five Conclusion 57 Recommendation 58 References 60 X List Of table Title No Table (1) Age distribution 34 Table (2)Rapid urease test 38 Table (3)Culture distribution 39 Table (4)Culture *Rapid urease test Cross tabulation 40 Table (5)Gender * Culture Cross tabulation Table (6)Occupation * Culture Cross tabulation Table (7)Residence * Culture Cross tabulation 41 42 43 List Of Fig Title No 33 Fig (1) Gender distribution Fig (2 Residence distribution Fig (3) Occupation distribution Fig (4 Endoscopy result Fig (5 Culture * Endoscopy Result Cross tabulation Fig (6 Clarithromycin sensitivity test Fig (7 Metronidazole sensitivity test Fig (8 Amoxicillin sensitivity test Fig (9)Tetracycline sensitivity test Fig (10) Commiphora myrrh sensitivity test (dil 1 Fig (11) Commiphora myrrh sensitivity test (dil 2) Fig (12) Commiphora myrrh sensitivity test (dil 3) Fig (13) Commiphora myrrh sensitivity test (dil 4 XI 35 36 37 44 45 46 47 48 49 50 51 52 Introduction and Literature review 1.1 Peptic Ulcer: A peptic ulcer is a sore on lining 0f the stomach or duodenum which is the beginning of small intestine .It refer to an ulcer in the lower esophagus ,stomach, duodenum in jejunum after surgical anastonsis to stomach or rarely in the ileum adjacent to meckel’s divverticulum ,in acid and pepsin play major pathogenic role(1,2 ). An ulcer in the lining of the stomach is called a gastric ulcer and the ulcer on upper part of the small intestine or duodenum called duodenal ulcer. In the US, duodenal ulcers are three times more common than gastric ulcers. The lining of the stomach is a layer of special cells, chemicals and mucous that prevents the stomach from being damaged by its own acid and digestive enzyme. If there is a break or ulcer in the lining, the tissue under the lining can be damaged by the enzymes and corrosive acid . If the ulcer is small ,there may be few symptoms and the wound can heal on its own .If the ulcer is deep ,it can cause serious pain or bleeding and may eat completely through the stomach or duodenum wall. The ulcers are common world wide , it may affect up to10-15 % of the population at is variable but it is very common in Scotland and northern England more than in southern England ,is also common in India (3,4) and common in Africa especially in the west, and usually the most affected patient present with complication ,incidence of P.U.D is declining in the world especially the complicated type but still the gastric ulcer is common in the east especially in Japan ( pre-malignant ulcer ) (5), The prevalence of peptic ulcer is decreasing in many western communities. It sill affects at some time approximately 10% of all adult males. The male to female ratio for duodenum ulcer varies from 5:1 to2:1 in different communities while that for gastric ulcer is 2:1 or less (2). In Sudanese patients peptic ulcer was found in 17% of 2500 upper gastrointestinal endoscopies (6) in other study on 12443 upper gastrointestinal endoscopies the active duodenal ulcer was 10-8% with seasonal variation seen with great incidence in January, February and lower incidence in July, August in comparison with the rest of year .(1,7,8).in other studies in Sudan the prevalence of P.U.D is about 18-30% so it is a very common disease .It effects predominantly, the younger age group of which a large number of patient presented with complications (3,9) Katelaris et al .,(10) in heir study of dyspepsia ,H. pylori and peptic ulcer in the randomly selected population in India found that prevalence of 1 active peptic ulcer in 197 male subjects was 6,6% with a further 6,6%of subjects has definite evidence of scaring or deformity (10) .In Misra et al.(11) study in India on H. pylori positive asymptomatic healthy subjects were 2,8% (11) . In Italian (12) study The prevalence was as higher as 22% in a group of 121 individuals with H. pylori infection (12) in asymptomatic healthy blood donors Peptic ulcer is common in every 10 Americans develops an ulcer of some time in his or her life. The main cause of an ulcer is bacterial infection but some ulcers were caused by long- term use of non steroidal anti-inflammatory agents (NSAID) like aspirin and ibuprofen . In few cases, cancerous tumors in stomach or pancreas can cause ulcer . 1.1.2 causes of peptic ulcer : The major factor to be examined are H. pylori ,non-steroidal anti-inflammatory drugs (NSAIDs),smoking stress ,alcohol ,dietary factors ,physical activity and heredity (13) . Since the Nobel prize-winning demonstration of the role of H. pylori in peptic ulcer ,there has been a widespread assumption that H. pylori is the cause of P.U and so implicitly of the epidemic (13,14) Baron and Sonnenberg (15) have suggested an epidemic of a potent strain of H. pylori sweeping the world was the cause of the ulcer epidemic ,and there are temporal, geographic and theoretical arguments to support this. The people infected with H. pylori have arlativ risk of 1.6-5.7 (mean 3.3)of developing PU compared with non-infected people (13,16,17) calculation of the population attributable risk (ie, the proportion of disease cases that can be attributed to a particular factor) shows that ,in recent series, H, pylori accounts for only about 50% of peptic ulcer (18) . ` Non-steroidal anti-inflammatory drugs (NSAIDs) (13,19,20). Despite a large body of evidence suggesting a role of non-steroidal anti-inflammatory drug (NSAIDs) in causing ulcer especially in elderly women (13). long− term use of non steroidal anti−inflammatory drugs (NSAIDs) is the second most common cause of ulcers .About 5-10% of duodenal ulcer disease patients and 30% of gastric ulcer patients do not have evidence of H .pylori infection .these ulcer presumably due to ASA, NSAIDs or some other agents of injury(13).About tow of every three patient on long-term NSAIDs have some gastro duodenal mucosal lesions. most of which were superficial (corrosions, rhanguse,etc) (3,13) Non-steroidal anti-inflammatory drugs (NSAIDs) provide effective management of pain 2 and inflammation ,but are associated with the formation of peptic ulcer and increased risk of peptic ulcer hemorrhage and perforations (serious gastrointestinal events)in the range o.3%to2.5% per year(20,21,22) Lifestyle Factors.: Although lifestyle factors (e.g. chronic stress ,dietary factor ,smoking ). Smoking : there is evidence that smoking increased the risk of peptic ulcer .An OR of 2.2 is typical ,and a 40-year study of male doctors in the U.k has shown a threefold increase in the risk of death from peptic ulcer in current smokers.(13,29) Alcohol : there is little evidence of an association between alcohol use and peptic ulcer .A study of Doll et al found no association in 13 year of follow-up (13,25). With coffee ,sugar ,salt there is little evidence of a link between them and duodenum ulcer (26,27,28) . Hereditary : A role of hereditary factor in peptic is Cleary delineated by several Scandinavian studies of large groups of monozygonic and dizygonic twins, reared together and separately .the evidence indicates that 39% -62% susceptibility to peptic ulcer is explained by hereditary factor ,the rest by environmental ones (29,30).There is also a major role for heredity in H. pylori acquisition (63% attributable to genetic factors), but genetic influences for developing peptic ulcer independent of those for acquiring H .pylori and the transition of H. pylori positivity to peptic ulcer is due to environmental factor (31). Stress : The sparse evidence for a link between stress and peptic ulcer is beset with methodological problem .A follow-up of 5388people in the first US National Health and Nutrition Examination Survey (1986-1992)found a clear positive dose –response curve . Those with the highest level of stress had an adjusted a relative risk of developing peptic ulcer (31). - The least common major cause of peptic ulcer disease is the Zollinger−Ellison syndrome (ZES).\ among patients with peptic ulcers. The mean age at onset is 45 to 50 years, and men are affected more often than women. ZES should be suspected in patients with ulcers who are not infected with H .pylori and have no history of NSAID use. -Rarely, certain conditions may cause ulceration in the stomach or intestine , including · Radiation treatments. · Bacterial or viral infections. · At 50 years old or older . · Physical injury. . Burin 3 1.1.3 Symptoms of peptic ulcer : Pain is the most common symptom. The pain usually: Is a dull, gnawing ache; Comes and goes for several days or weeks; Occurs 2 to 3 hours after a meal; Occurs in the middle of the night (when the stomach is empty) , and is relieved by food. 1.1.3.1 Other symptoms: Other symptoms of peptic ulcer include Weight loss. Poor appetite. Bloating. Burping. Nausea. Vomiting. Some people experience only very mild symptoms, or none at all. 1.1.3.2 Emergency Symptoms : Sharp, sudden, persistent stomach pain. Bloody or black stools. Bloody vomit or vomit that looks like coffee grounds. They could be signs of a serious problem, such as: Perforation-when the ulcer burrows through the stomach or duodenal wall. Bleeding - when acid or the ulcer breaks a blood vessel. Obstruction - when the ulcer blocks the path of food trying to leave the stomach . 4 1.1.5 Treatment of peptic ulcer: Treatment of peptic ulcer is currently in astate of major change .In the past therapy that consisted of acid-neutralizing or acid- secretary inhibiting drugs was useful to control the symptoms. (3). people whose ulcers are caused by NSAIDs or other drugs should stop using these drugs. Healing will begin almost immediately. Also medications are recommended to reduce acid damage during healing .These may include anti-acids to neutralize gastric acid or medications that decrease the amount of acid produced by the stomach. 1.2 Helicobacter : In the aearly 1980s, Warren and Marshal, two Australian physicians, reported the presence of an unidentified gram-negative curved and spiral-shaped bacillus in gastric epithelial tissue of patient with chronic gastritis .Originally called Campylobacter pylori this organism was later renamed Helicobacter pylori when the organism was found to have characteristics that differed from those of true Campylobacters (33).. In 1982. Warren and Marshal were the first to culture and identify what is now known as H .pylori and to establish the association between the presence of this organism in mucosa and occurrence of histological gastritis (34,35). Within a few years of publication of Warren and Marshal’s work many reports appeared worldwide. confirming the close association between H .pylori and chronic active gastritis .as well as with gastric and duodenal ulcer .The historical association between bacteria and peptic ulcer disease are described by Rathbone and Heatley (1992) (34) The organism was named Campylobacter pyloridis by Marshal et al (1994).but this was later changed to the more grammatically correct Campylobacter pylori. Further studies showed that the organism sufficiently from true Campylobacter to justify the formation of a new genus Helicobacter.(34,36).It soon became apparent that similar organism colonized the stomach of a wide variety of animals other than humans .and certain spiral bacteria colonized intestines of rodents and other animals belonged to Helicobacter .Helicobacter and Campylobacter, Arcobacter and Wolinella was shown to belong to a distinct bacterial grouping. RRNA super family VI .based on 16s RNA-DNA hybridization analysis(37) and the classification was defined by 16s r DNA phylogenic analysis which placed Helicobacter and these other genera in the epsilon subclass of class proteobacteria . Although specific fatty acid profile .specific ultra structure. 5 Respiratory quinines. growth requirements and enzyme characteristics were originally described to distinguish Helicobacters .the use of 16s rDNA analysis is crucial for their classification as there are no other consistent taxonomic markers to facilitate separation of Helicobacter from allied genera such as Campylobacter and Arcobacter. Helicobacter pylori infects about half of the world’s population. was widely accepted as a cause for the development of gastritis (38,39,40). Today, H. pylori is not only considered a causative agent of chronic type B gastritis and peptic ulcer disease, but also an important risk factor for gastric cancer and MALT-lymphoma . 1.2.1 Characteristics: H. pylori is a curved or spiral shaped Gram negative bacillus with up to three windings (40). It measures 3-5 µm in length and approximately 0.5 µm in diameter. There are two to six unipolar sheathed flagella (41), which are essential for the bacterium’s motility. Under unfavorable conditions H. pylori can transform into a coccoid form, which probably reflects degenerative changes (42). The microaerophilic bacterium possesses both oxidase and catalase activities. The complete genome of a H. pylori strain was sequenced by Tomb et al . (1997) (43 ) 1 2.2 .Habitat : Humans appear to be the only natural host of H. pylori identified to date, although some studies suggest that animals also may act as a reservoir, as reviewed by Mitchell (38,44). The surface of the stomach mucosa is the major habitat of H. pylori and the majority are located adjacent to surface and pit gastric epithelial cells (34) 1.2.3 Species : There are more than 20 species ascribed io the Helicobacter genus. Chronic infection of various host with gastric Helicobacters such a H. pylori, H. felis ,H. mustelae and H. bizzozeronii has been associated with a spectrum of pathologies such as gastritis, mucosa-associated lymphoid tissue lymphoma(45,46,47)and in the case of H .pylori , peptic ulcer and gastric adenocarcenoma in humans (48,49).Other related bacteria such as H. hepaticus, H. bilis, H. pullorum and Helicobacter sp flexispira colonize the enterohepatic niche of animals and humans, and many play role in enterohepatic and gastroenteritis (50,51).And other spp such as H.acinonychiis ,H.nemestrinae,H 6 .mustelae (34) ,H.heillmannii,H.canadensis andH.bills ,H.bovis ,H. suis and H. Suncus 2.2.4 Antigenic structures: Helicobacter have the typical cell wall structure of gram- negative bacteria comprised of lipopolysaccharide (LPS) attatched to a semi permeable outer membrane apeptidoglycan layer .and an inner cell membrane. The fatty acid composition of H. pylori is distinctive and one of the main criteria for Campylobacter’s .It is characterized by long –chain fatty acid composed predominantly of tetradecanoic (14 :0) and 19carbon cyclopropan (19-0cyc)acid acids with lower amounts of hexadecanoic (16:0) octadecanoic (18:0) . octadecanoic (18:1) and linoleic (18:2 )acid Phosphatidylethanolamine (79.1%) .lysophosphatidylethanolamine (16%).and phosphatidylcholine (1.9%) constitute the polar head groups of neutral phospholipids. Acidic phospholipids contain phosphatidic acid (52.7% )and phosphatidylserine (47.3%) H. pylori does not possess the methyl-substituted menaquinones (thermo plasma quinones ) present in Campylobacter species. Cholesterol glycosides are a unique characteristic of the lipid content of various Helicobacter sp.(34,52) 1.2.5 culture and colony morphology : H. pylori is strictly microaerophilic and Co2 (5-20%)and high humidity are required for growth.(34,53 ) H. pylori requires media containing supplements similar to those used for Campylobacter blood .serum .starch .or charcoal. However H. pylori is inhibited by bisulfate in the ferrous sulfite-sodium metabisulfite -sodium pyruvate (FBP) Campylobacter ‘aerotolerance’ supplement .(34) The good growth has been obtained by using Brucella, brain-heat infusion (BHI) and cryptic Soya agar with 5% sheep blood and using of modified Thayer- martin agar as a selective media for isolation of Helicobacter pylori in mixed cultures incubated at 37oC.in humid microphilics environment (5% O and 10% Co2 and 85% N2 ) for 3 - 6 days.(53) Poor growth is observed on commercially prepared chocolate agar and there for this media is not recommended because Helicobacter pylori is susceptible to cephalothin and will not grow on any selective media containing cephalosporin. 7 The colonies of Helicobacter pylori are small, they grow bigger than 2mm in diameter if incubation extended beyond 1week. gray, translucent, convex (34,53) weekly Bhemolytic. on 5%horse blood agar. motility is weak or absent when grow on agar.(34) Gram stain reveals pale-staining curved gram-negative with characteristic gull-wing and U shapes. 1.2.6 Pathogenesis : H. pylori does not invade the host tissue but rather is restricted to the mucus overlaying the gastric epithelium. During its colonization of the gastric mucosa H. pylori is challenged by the innate and adaptive immune response, and the organism has developed strategies of avoidance and subversion of the immune system. The virulence factors described above support the organism’s ability to establish a persistent infection, but mechanisms of immune evasion such as antigenic shedding of urease, antigenic variation and a possible immune suppression by H .pylori may contribute as well . Urease in an important immunodominant protein that makes its way to the cell surface, where it is not covalently attached (54), and free urease or urease adsorbed to bacteria has been detected in the gastric mucosa of H. pylori infected patients (55,56). Shed urease could bind to secretory IgA and thereby overcome its antibacterial activity . After the sequencing of the H. pylori genome, sequence similarities among a group of outer membrane proteins have become evident. It seems feasible that recombination events could lead to mosaic organization and thus contribute to antigenic variation (57) In vitro experiments (58,59) have shown that the proliferation of peripheral blood mononuclear cells is decreased in H. pylori infected patients compared to healthy blood donors. Thus some researchers have argued that H. pylori infection might lead to a suppression of the host cellular immune response. Both bacterial virulence factors and damage caused by the host inflammatory immune response contribute to the pathogenesis of H. pylori gastritis . Direct cell damage can be caused by vacA and urease, which both lead to vacuolisation of the gastric epithelial cell in vitro . Indirect damage to the host is caused by a vigorous immune response. H. pylori activates the proinflammatory transcription factor NF.B in gastric epithelial and 8 monocytic cells, probably via CagA dependent and independent pathways in different cell types (60,61). This pathway of NF.B activation, together with other pathways, results in epithelial production of IL-8, a chemotactic factor for human neutrophils (61,62). The chemotactic effect of IL-8, together with a chemotactic effect of H. pylori surface proteins (55), leads to an infiltration of the gastric mucosa with neutrophils and monocytes, causing inflammation and mucosal damage . H. pylori adheres to and is phagocytosed by the infiltrating cells. Since it has been shown that H. pylori is able to activate a respiratory burst in human neutrophils and monocytes (63,64) mucosal damage may be due to the oxygen radicals produced in this reaction . Additionally, molecular mimicry between H. pylori LPS and host antigens might contribute to mucosal damage through autoimmune reactions. The LPS of 85% of H. pylori strains is composed of Lewis x and/or Lewis y antigens, human blood group glycoantigens whose epitopes may also be present on the beta chain of the H+/K+ATPase of the human gastric parietal cell. Thus H. pylori LPS is able to stimulate strong anti-Lewis x and anti-Lewis y responses in humans (65,66). These findings suggest that molecular mimicry-induced autoimmune reactions could contribute to the pathogenesis of H. pylori infection . There are data suggesting that H. pylori affects serum levels of gastrin, a peptide hormone that is produced by gastric G-cells and stimulates gastric acid secretion. Studies comparing the serum gastrin levels of healthy and H. pylori-infected individuals indicate that infection is correlated with increased serum gastrin levels. However, the acid secretion was only elevated in patients presenting with duodenal ulcers compared to healthy control individuals, while it was normal in asymptomatic H. pylori-infected patients (67). This increased acid production might also contribute to mucosal damage. 1.2.7 Diseases : Diseases associated with H. pylori include chronic gastritis, peptic ulcer disease, gastric cancer and MALT-lymphoma . Today the bacterium is considered the main causative agent of chronic type B gastritis (68) The inflammation primarily affects the antrum and is characterized by neutrophilic and 9 lymphocytic infiltrates and distinctive epithelial degenerative changes (69). H. pylori is an important risk factor for peptic ulcer disease, and infection has been diagnosed in 60%-100% of gastric and 90%-100% of duodenal ulcers cases, although in the duodenum the bacterium has only been detected in areas of gastric metaplasia indicating its tissue specifity (70). Eradication of H. pylori from H. pylori-positive peptic ulcer patients provides the most effective treatment resulting in ulcer healing and low frequencies of relapse (71,72) The chronic inflammation caused by H. pylori can result in mucosal atrophy, metaplasia and dysplasia, thereby creating the bases for a malignant transformation (73,74). Therefore Helicobacter infection is associated with an increased risk of gastric cancer (75,76) . Clinical and epidemiological studies provide data for an association of the bacterium and MALT lymphoma. H. pylori infection has been diagnosed in over 90% of MALT lymphoma patients (77), and antimicrobial eradication therapy can result in tumor remission in clinical studies (78). In vitro, the growth of isolated lymphoma cells required a T cell activation induced by H. pylori (79,80) 1.2.8 Diagnosis: Various tests are available to assist in diagnosis of H. pylori infection .These test can be categorized into those that are based on direct assessment of gastric biopsies (invasive) and indirect tests (noninvasive )that detect an immunological response (i.e. antibodies against H. pylori ) or metabolic products (i.e.urease activity) of H. pylori (34) The gold standard for the detection of H. pylori has been defined as culture, or histopathological examination of gastric biopsies. Depending on the experience of the investigator .In order to optimize the diagnosis of H. pylori .It is usually recommended that several tests be used together .The choice of a particular test will depend on locally available facilities, cost considerations, and clinical circumstances in which the diagnosis of H. pylori is to be made. 1.2.8.1 Histology: Histology is currently the gold standard for diagnosing H. pylori infection. The organ ism can be identified on a routine hematoxylin-eosin stain but special stain 10 (e.g.Geimsa, Warthin-starry )may be even more accurate .At least two samples should be evaluated, regardless of the stain used . Because H. pylori infection causes antral inflammation ,some investigators suggest that absence of inflammation on biopsy is the most dependable finding to use for exclusion of infection (negative predictive value 100%) (3,81) . 1.2.8.2 Culture : The most specific method to diagnose infection is culture of H. pylori from gastric biopsies, but its sensitivity depends on both the biopsy transport conditions and expertise available in the individual laboratory (34,82). However, H. pylori is a fastidious, slow growing organism that requires special culture conditions. So relying on culture alone can mean missing a proportion of infected cases for technical reason, Including overgrowth of other bacteria and low bacterial load. Attention to transport conditions of biopsies is particularly crucial for an adequate diagnostic yield . Biopsy specimens should be transported in a moist state, must be cultured within 4-6h of being taken. Storage beyond this time should be at 4oC, or at 20oC if the period is more than 2days. Specimens can be kept in Stuart semisolid transport medium for 24h if stored at 4oC (83).No transport medium is used universally, but the various suggested transport media for biopsy samples, include normalsalne,20%glucose,and Stuarts medium(84).An in-house Helicobacter transport medium used successfully for several years for both biopsies and cultures comprises brain heart infusion broth (3.5%),yeast extract (2.4%) sterile horse serum (5%)and antibiotic supplement (Vancomycine , Trimethoprim ,cephsoludin, amphotericin ) (85). Selective media should be used together with a non selective fresh blood-based agar..in order to ensure optimal recovery of H. pylori, plates should be incubated in microaerobic environment at 37oC under humid condition for at least 5-7 days before being discarded. Colonies may be visible after 3-5days of incubation but may take longer to appear on primary isolation. 1.2.8.3 Rapid urease test: H. pylori produces such abundant urease that the enzyme can be detected in specimens of infected gastric mucosa placed directly in a solution of urea with phenol red as an indicator. In the original test, Christensen urea broth was used but unbuffered urea solutions .If freshly prepared .and the use of gels instead of broth give quicker result 11 (34,86,87)A number of modifications have been described and kits are now widely available from commercial sources (e.g. Campylobacter-like organism(clo)test ). The test can have a sensitivity of at least 80% and specificity approaching 100% when the reaction is positive within 1h. false positive may occur by contamination with ureaseproducing bacteria from the oral cavity .In clinical practice ,biopsy urease test result should be read within 24h It has the advantage of diagnosing H. pylori status in most cases soon after endoscopy, which is helpful for the clinician planning therapeutic interventions. Test kits are accure of gastric biopsies (34,88). 1.2.8.4 Urease breath test : The urea breath test identifies active H. pylori infection through the organism’s urease production. The patient ingests urea labeled with either the nonradioactive isotope carbon 13 (13C)(Breath Tek UBT for H. pylori, Meretek Diagnostics, Inc, Lafayette, CO) or the radioactive isotope carbon 14 (14C) (PY test, Kimberly-Clark Corp, Draper, UT). If H. pylori is present in the stomach, hydrolysis occurs and produces Labelle carbon dioxide, which is detectable within a few minutes in the patient’s breath. The labeled urea is typically given to the patient with a test meal to delay gastric emptying and increase contact time with the mucosa. After urea ingestion, breath samples are collected for up to 20 minutes by exhaling into a carbon dioxide–trapping agent. Though the amount of radiation in the 14C urea breath test is less than daily background radiation exposure,(89,90) the 13C test is preferred in children and pregnant women.(91) Recently, a new card test for 14C urea has been described that uses a flat breath card that is read by a small analyzer, providing a nearpatient testing option in primary care settings. The urea breath test detects active H. pylori infection and is highly accurate, with a weighted mean sensitivity and specificity from published trials of 94.7% and 95.7%, respectively (92) 1.2.8.5 Serology : Serologic testing detects the presence of specific IgG antibodies to H. pylori in a patient’s serum. These antibodies are present in serum about 21 days after infection and can remain present long after the organism is eradicated. They can be assessed quantitatively using enzyme-linked immunosorbent assay (ELISA)and latex 12 agglutination techniques or qualitatively using office-based kits. Dozens of different serologic tests are commercially available.( 89) Advantages of the serologic tests are their wide availability, their rapid results, the fact that they require no specialized equipment or techniques, and their low cost relative to active tests. For these reasons, serologic tests were the mainstay of H. pylori diagnosis for a number of years.(89) The major disadvantage of serologic tests is that they cannot distinguish between active infection and previous exposure to H. pylori because serologic testing detects only antibodies, a positive serology result can occur in three very different patient groups(93) 1. Those with detectable antibody and active H. pylori infection (true-positive for antibody, infected). 2. Those with detectable antibody but not actively infected (true-positive for antibody, not infected). 3. Those never infected and with no antibody detectable (false-positive result). This distinction is critical because eradication therapy is of no clinical value in the second and third groups. As more and more people are successfully treated for H. pylori in a population, the ranks of the “true-positive for antibody, not infected” group (group 2) will grow. Of course, the inability to distinguish between active and past infection also renders serologic testing useless for confirmatory testing to ensure H. pylori eradication following treatment to cure the infection. This inability to distinguish between current and past infection contributes to the other major shortcoming of serologic testing that it is less sensitive and specific than the active noninvasive tests for H. pylori (92). 1.2.8.6 Stool antigen test : The stool antigen test is an enzymatic immunoassay (ELISA) that identifies H. pylori Antigen in stool specimens through a polyclonal anti- H. pylori antibody (Premier Platinum HpSA, Meridian Bioscience, Inc, Cincinnati, OH). In addition, a rapid stool antigen test (Immuno card STAT! HpSA, Meridian Bioscience, Inc, Cincinnati, OH) is available. Using the rapid assay, a diluted stool sample from the patient is dispensed into the sample port of the test device; after 5 minutes of incubation at room temperature, the device indicates a positive or negative result, providing a near-patient testing option in primary care settings(89). 13 The ELISA stool antigen test detects active H. pylori infection and is highly accurate, with a weighted mean sensitivity and specificity from published trials of 93.1% and 92.8%,respectively (89,92) rates that are virtually the same as those for the urea breath test. Islam et al. (2005) evaluated the usefulness of HpSA before and after eradication therapy on 127 adult patients. All patients underwent HpSA testing and gastroscopy with biopsies. Those who were found to be H. pylori-positive received triple therapy of clarithromycin, amoxicillin and omeprazole for seven days. HpSA was compared with histology, urease testing, or a combination of the two for pretherapy testing. After a period of six to eight weeks, post-treatment testing for confirmation of eradication was done using the UBT and HpSA. The sensitivity and specificity were 79% and 92%, respectively, for HpSA when compared to combined urease and histology as the reference standards. A sensitivity of 67% and specificity of 100% were reported for HpSA when compared to UBT used as the reference standard for post-treatment testing. The authors concluded that “in this prospective study, HpSA was found to be a reasonably useful diagnostic test for H. pylori infection .(94,95) 1.2.8.7 Near patient test : Rapid office-based tests using whole blood have been developed as they are quick and easy to perform. but sensitivity and specificity vary widely .Their inaccuracy therefore precludes there use as diagnostic test in genral practice setting(96). 1.2.8.8 Salivary and urine antibody : The use of commercial assays to detect anti-H. pylori IgG antibodies in saliva or urine are attractive alternatives as they are completely noninvasive and easy to perform. The accuracy is unacceptable (sensitivity 81% and specifity 73% ) (97).However .data on urine antibodies assay indicate an accuracy comparable to that of the serum ELISA in Japanese (98) and European population (96). 1.2.8.9 Molecular test : There are no commercially available assays for the detection of H. pylori in gastric biopsies even though several validated genus and species-specific probe hybridization and PCR assays have been described and have recently been reviewed (99) .The method with the potential for greatest sensitivity is detection of H. pylori-specific DNA by PCR .Gastric biopsy material and gastric juice aspirates have been used for 14 PCR diagnosis targeting various DNA sequences including regions of 16S rRNA gene (100). urease subunit genes (101).The vacA gen (102).and a portion of a gene encoding a spescies-specific 26 kDa protein (103).Results with these PCR tests have yielded ranges of sensitivities and specificities depending on the material analyzed and the assays (99). Molecular techniques may be become more relevant for the diagnosis of H. pylori. 1.2.8.10 String test : The swallowed string test (Enterotest ) is minimal invasive approach as an alternative to endoscopy for direct sampling of gastric fluid, although there is no information on its use in clinical practice . samling of gastric juice provides a good measure of the infecting strain population shed from the gastric mucosa (104) so analysis of the string sample by culture or PCR could be informative when its accuracy has been established.(34). 1.2.9 Immunity: Patients infected with H pylori develop an IgM antibody response to the infection . Subsequently, IgG and IgA are produced, and these persist, both systemically and at the mucosa in high titer in chronic infected patents 1.2.10 Transmission: Its transmission has not been completely understood. Direct person to person transmission is considered to be the most likely mode and it is believed that the transmission either follows the fecal-oral or the oral-oral route. Fecal-oral (1,38,131) transmission gained importance by the detection of H. pylori in the faeces of infected patients (132), while studies comparing the distribution patterns of H. pylori with Hepatitis A virus, an organism transmitted by the fecal-oral route, suggest that this transmission mode may be of limited importance (133). There is evidence that acquisition of infection takes place predominantly in early childhood (134), and the host usually remains infected for a lifetime. Transmission of the bacterium among adults seems less frequent although it seems favoured when there is close personal contact, as there are higher prevalences in institutions (135). 15 1.2.11 Epidemiology: childhood (136,137), close person to person contact (138,139), and low socioeconomic status (140). Thus the prevalence of H. pylori infection ranges from approximately 20 to 50% in industrialized countries to over 90% in developing nations (141,142). As determined in a study of the Robert Koch Institute in 2000, the prevalence of H. pylori infection for the total population of Germany is 40% (143) It is estimated that 50% of the world’s population is infected with H. pylori. Infection rates ،like for many other infectious diseases, correlate with poor living conditions H. pylori is present on the gastric mucosa of less than 20% of persons under age 30 but increases in prevalence to 40-60% of persons age 60 including persons who are asymptomatic. In developing countries the prevalence of infection may be 80 %or higher in adult. \ 1.2.12 Treatment: Eradication of H. pylori is probably one of the most frequently prescribed antibiotic based complex therapies due to the widespread rate of colonization of the bacteria in humans. management of H. pylori infection in different gastrointestinal diseases is guided by international and national guidelines and recommendations (e.g. Maastricht Consensus reports for Europe).(105) . At present, clarithromycin (Cla), amoxicillin (Am) and proton pump inhibitor (PPi) based triple therapy regimen constitutes the most generally accepted first line empirical treatment for H. pylori infected patients world-wide. However, the growing number of reported therapy failures has long prompted clinicians to seek more effective solutions. (106.107). These efforts, based mostly on empirical observations with different antibiotic combinations, have not led to widely accepted, conclusive therapy protocols, so far. When selecting a therapy to eradicate H. pylori, duration of treatment and adverse effects should be considered (108) Until recently, the recommended duration of therapy for H. pylori eradication was 10 to 14 days. The most widely recommended regimens are summarized in.37Studies evaluating one-, five-, and seven-day regimens to eradicate H. pylori are summarized in(108,109,110). Although not proven, potential benefits of shorter regimens include better compliance, fewer adverse drug effects, and reduced cost to the patient.(108) 16 1.2.12.1 Firest-line treatment : The best validated first-line treatments for H. pylori include clarithromycin-based triple therapies consisting of a proton pump inhibitor (PPI), clarithromycin, and either amoxicillin or metronidazole and bismuth-based quadruple therapies consisting of a histamine receptor antagonist or PPI combined with bismuth, tetracycline, and metronidazole. Where available, ranitidine bismuth citrate (RBC) can be substituted for a PPI in clariithromycin triple therapy .These regimens currently yield eradication rates ranging from 70%–85%. Triple therapy employing a PPI with clarithromycin and amoxicillin is the most widely endorsed first-line regimen for H. pylori eradication(111,112,113) Any of the currently available PPIs may be used with equivalent treatment (114,115)With the exception of esomeprazole which can be prescribed once daily, it is important that the standard dose of a PPI be prescribed twice daily to maximize treatment efficacy.(116) RBC is sometimes used in place of a PPI in countries outside the United States (where it is not commercially available) with at least equal and perhaps greater efficacy.(117) Metronidazole can be used as an alternative to amoxicillin, particularly Bismuth-based quadruple therapy is another option in penicillin allergic patients which yields similar eradication rates to clarithromycin triple therapies(.118,119,120) . Recently, simplified twice-daily dosing regimens for bismuth quadruple therapy have been successfully used in clinical trials.(121) It is worth noting that the dosing of metronidazole used in the various bismuth quadruple therapies has not been entirely consistent across studies. As higher doses of metronidazole (500 mg) may provide better cure rates than lower doses (250 mg),caution must be exercised when interpreting the data from comparative studies and pooled analyses involving quadruple therapies. Administration for use in the United States. A recent meta-analysis of 7 studies involving more than 900 patients found that a 14-day course of clarithromycin triple therapy provided better eradication rates than a 7-day course of therapy. There was also a trend toward improved efficacy with10 days of therapy compared to 7 days of therapy which did not reach statistical significance.(122) Due to falling eradication rates with clarithromycin-based triple therapy, it is essential to take every opportunity to optimize treatment success. clarithromycin triple therapy, particularly in regions such as the United States where eradication rates have been 80% or less with shorter durations of therapy. Although some promising data exists on the effectiveness of 17 ultra short course of therapy,(111,123,124) treatment duration of less than 7 days cannot currently be recommended 1.2.12.2 Second-line therapies : Even with the current most effective treatment regimens, About 10-20% of the patients will fail to eradicate the infection and will remain H. pylori positive after 4 weeks or longer .Failures are due mainly to bacterial resistance or poor compliance. Widespread resistance to antibiotics used in eradication therapy. In particular metronidazole and clarithromycin, is a source of growing concern because of its impact on eradication .The clinical relevance of antibiotic resistance is increasingly accepted as an issue and its importance in therapy has been high lighted in several recent studies (125,126) . An optimal strategy for retreatment after initial failure of eradication has not yet been established, but the recommended second line therapy according to the Maastricht II2000 report is use of quadruple therapy a PPI with bismuth ,metronidazole ,and tetracycline (an antibiotic un likely to have been used previously in front-line therapy ). It is advisable that the antibiotic susceptibility of the organism is determined before retreating because of high resistance rates in some populations to metronidazole . The use of ranitidine-bismuth-citrate-based triple therapy is another possibility for retreatment (127). 1.2.12.2 Resistance: Although first-line therapy will successfully eradicate the bacteria in most infected patients, antibiotic resistance of H. pylori is a growing concern.(128,129 ).Resistant H. pylori has been documented in cases of failed eradication therapy based on biopsy and culture results and is of great concern in patients at high risk for complications of H. pylori infection. In one small trial, 70 percent of patients failing one or more regimens responded well to triple-drug therapy that included pantoprazole (Protonix), amoxicillin, and levofloxacin (Levaquin) for 10 days (130) A meta analysis of current literature on treatment of resistant H. pylori showed some benefit in using quadruple drug therapy, including the addition of clarithromycin to ranitidine (Zantac),bismuth, and amoxicillin (1g twice daily)therapy, as well as a combination of proton-pump inhibitors (standard dosage for 10 days),bismuth, metronidazole (Flagyl), and tetracycline. (129) 18 Regimens that include rifabutin (Mycobutin), 300 mg per day, also have been successful in 38 percent of resistant cases.(128). 1.3.1 Medicinal plants: The medicinal plants were known since old ages and were handled by many people as traditional medicine to treat many diseases. Statistical purposes to use these traditional medicines were found very high in developing countries and Sudan is one of them. To use traditional medicine which was very primitive not scientifically studied for the right quality and quantity and the side effect on users, there are many scientific institution and researchers as individual their attention to study many plants that are used in traditional medicine, to extract the useful ingredient without the harmful material. Commiphora myrrh is one of the medicine plants that are commonly used in Sudan in traditional medicine for the treatment of many diseases. This plant is found in great quantity in North-East Africa, collected in Southern Arabia and Iran. [ 1.3.2. The activity of medicine plants: Effective efforts have been made over last fifty-year to find new antimicrobial agents the major part of the reported investigations was concerned with lower plants with special attention being paid to different species of Streptomycets and some fungi . However, a number of reports indicated new source of anti-microbial agents from higher plants (144) Beloy,et al(1976) studied 106 species belonging to44 families for antimicrobial activity 9 plants showed high antimicrobial activity Thirty-three plants of Pakistan origin screened by Ikram and Inamul-Hag(1980) for antimicrobial activity (144). Wondergam and grand (1984) examined 33 species (used against infectious diseases by the diolaof southern Senegal) for antimicrobial activity. Of these 28were active against such organisms as Staphylococcus aureus, Bacillus subtilis and Asperigillus niger (144).. Forty-five species of Somalian medicinal plants screened by Elmi et al (1986) for antimicrobial activity against (Staphylococcus aureus, Bacillus subtilis) They found 19 that, thirty species showed activity against Gram-positive bacteria . (144). Elagimi et al (1998) screened 114 extracts of Sudanese plants used in folkloric medicine for their anti-bacterial activity against (E. coli, Staphylococcus aureus , Bacillus subtilis , P. aeruginosa) Of these,83,(73%) extracts showed significant antibacterial activity. (144). 1.3.3. Commiphora myrrh : As mentioned by Guenther(145), myrrh (also called heerabol-myrrh or bitter myrrh) is gum-resin obtained from several species of Commiphora (fam. Burseraceae), notably C. Abyssinic(Berg) Engler, oofC. schimperi (Berg) Engler, and C. myrrh (Nees) Engler var molmol Engler. Genus Commiphora comprises more than 200 species, all native to Africa, Arabia, Madagascar and India. In order to collect gum, the natives make incisions into the bark, causing the exudation of a yellowish oleo resin. Exposed to the air, this dries, hardens and turns reddish-brown..(146) Myrrh is partly soluble in ethanol (30 % alcohol soluble material) and is also partly soluble in water and in ether. Since antiquity myrrh has served as a constituent of incense. Oil of myrrh is a valuable ingredient in perfumes (balsamic, heavy odour). The chemistry of myrrh..(146). Commiphora myrrh (also known as Commiphora molmol and Balsamodendron myrrh) of the Burseraceae family and is also known as bola, Myrrh is a large shrub or small tree that grows in the Middle East and Ethiopia and Somalia. A pale yellow oil drips from the cuts in its dull gray bark and hardens to form teardrop-shaped nuggets of myrrh, which are powdered for use as a healing herb. (147) Myrrh is referred to in the Bible. It was used by Egyptians in embalming mixtures. It was used as an aromatic for perfumes, funerals, and insect repellents. It is used today as an aid to repel tooth decay and gum disease. Ancient Greek and Roman physicians used the herb to treat wounds and prescribed it internally as a digestive aid and menstruation promoter (147,148). Contemporary herbalists recommend adding powdered myrrh to well-washed wounds as an antiseptic and consider a gargle made from the herb effective against sore throat, colds, sore teeth and gums, coughs, asthma, and chest congestion. Anti-microbial, astringent, carminative, anti-catarrhal,expectorant, analgesic,antiseptic, antispasmodic, emmenagogue, expectorant, stimulant, rejuvenative. 20 Myrrh is an effective anti-microbial agent that has been shown to work in two complementary ways. Primarily it stimulates the production of white blood corpuscles (with their anti-pathogenic actions) and secondarily it has a direct anti-microbial effect. Myrrh may be used in a wide range of conditions where an anti-microbial agent is needed. It finds specific use in the treatment of infections in the mouth such as mouth ulcers, gingivitis, phyorrhoea, as well as the catarrhal problems of pharyngitis and sinusitis. It may also help with laryngitis and respiratory complaints. Systemically it is of value in the treatment of boils and similar conditions as well as glandular fever and brucellosis. It is often used as part of an approach to the treatment of the common cold. Externally it will be healing and antiseptic for wounds and abrasions. Myrrh is a common ingredient in European toothpaste to fight the bacteria that cause tooth decay. Used in traditional Chinese medicinal herbs as antineoplastic agents and antitumor Myrrh may help prevent heart disease. Preliminary Indian studies suggest that it reduces cholesterol. The herb may also help prevent the internal blood clots that trigger heart attack. Myrrh appears in British Pharmacopoeia and other modern pharmacopoeias (149) Tincture of myrrh, prepared by extraction with 90% alcohol,(150)is used in mouthwashes and gargles for its astringent effect on mucous membranes ,particularly for mouth ulcers, gingivitis and pharyngitis. It has also been applied to the skin for wounds and abrasion (151) although there are reports of contact dermatitis developing as a result of topical application of myrrh –containing plasters (152).Other myrrh – containing products include toothpastes ,hairsprays, perfumes, aromatherapy oils and toiletries (153). Myrrh is also permitted to be used in foodstuffs in small quantities(154).Teething-gels containing myrrh have been used to relieve teething pain in infants(155). One of the newest developments in the uses of myrrh has also been the most controversial and relates to its role in treating Schistosomiasis (148). 21 1.3.3.1 Active Compounds: Volatile oil, containing heerabolene, cadinene , elemol , eugenol cuminaldehyde, numerous furanosesquiterpenes including furanodiene, furanodienone, curzerenone, lindestrene, 2-methoxy furanodiene and other derivatives. Resins including a-, b- and g-commiphoric acids, commiphorinic acid, heeraboresene, a-and b-heerabomyrrhols and comm Gums, composed of arabinose, galactose, xylose and 4-O- methylglucuronic acid 22 Objective of the study General: To study the effects of Commiphora myrrh in clinical isolate of Helicobacter pylori from peptic ulcer patient . Specific: 1. To determine The prevalence of Helicobacter pylori in G I.T. patients. 2. To Identify the isolates using standard techniques. 3. To Conduct sensitivity test to the Commiphora myrrh in comparison used antimicrobial agents with . . 23 Materials and methods 2-1 Study approach: Quantitative study aimed to identify causative agents of peptic ulcer disease and their susceptibility testing against Commiphora myrrh and commonly used antimicrobial agents 2.2 Study design : The study was designed as a descriptive study 2.3 Study area : The study area was facility based conducted in Khartoum state at Ibn Sina endoscopy department 2-4 Study variables: Frequency of peptic ulcer disease, antimicrobial sensitivity. 2.5 Study population: A total number of hundred patients suffering from gastritis, duodenitis, and peptic ulcer in Khartoum state at Ibn Sina hospital attending to endoscopy department Were included in this study. 2.6 Selection criteria : The selection criteria depend on the hospital attendance (in and out patients). only patients responding to the questionnaire 2.7 Ethical clearance: - Approval was obtained from University, Faculty and Department. - The consent was obtained ibn sina endoscopy unit hospital and from patients. 2.8 Material: 3.8.1 Culture media: Brain Heart Infusion broth Brain Heart agar Mueller Hinton Agar Oxoid – England Oxoid – England Oxoid - England 24 Exp 2/2008 Exp 2008 Exp 20011 2.8.2 Supplement : Skirrows supplement: Vancomycin Polymyxin bsulphate Trimethoprim lactate Amphotericin B Exp 2008 (10 mg/l) (250-300mg/l) (5mg /l) (2mg/l) 2.8.3 Antimicrobial disk Amoxicillin Tetracycline Metronidazole Clarithromycin (30 ug) (30 ug) (32 ug) (15 ug) 3/2008 3/2008 3/2008 3/2008 2.8.4 Chemicals & biological materials : Gram stain (Crystal violet,Gram Iodine ,Safranin,Ethyl Alcohol.) Hydrogen peroxide Glycerol Urease reagent (Urea ,Phenol red) Oxidase discs(tetramethyl-p&phenylene-diamine dihydrochloride ) Microaerophillic systems gas generation kits Horse serum Sheep blood 2.8.5 Instruments &glass ware : Autoclave Anaerobic jar Hot air oven Microscope Incubator Sterile plates Sterile pipettes 25 Sterile containers Sterile tubes Tube racks Standard loop Slides 2.9 Methods: 2.9.1 Collection of the samples : The samples were taken from 100 PUD patients by endoscopy at Ibn Sina Hospital in the period September 2006 to November 2007. Two biopsy specimens were taken from the antrum of the PUD patients one for rapid urease test on urea media and the other for culture on brain heart infusion broth media. 2 .9. 2 Rapid urease test : In sterile container 1 ml of urea media with few drops of phenol red as indicator was Placed .One of the two biopsy was placed in the mixture .the result observed by the change of the colour from yellow to pink due to break down of urea by urease enzyme which is produced by the organism to give ammonia and carbon dioxide which changes the media PH to alkaline that means the organism is H. pylori . Urease test vary according to the volumes of broth or agar, concentration of urea and phenol, and incubation temperature. 2.9.3 Culture: Isolation of H. pylori by culture is available diagnostic technique even a small number of organisms in the biopsy specimen is sufficient to provide a positive culture. To obtain optimal result it necessary to take great care in the preparation and transportation of the specimen (3). A culture can be performed on solid or liquid media .In clinical practice, a culture is required mainly if antibiotic sensitivity is to be tested . To isolate H. pylori the other biopsy specimen was placed in brain heart infusion broth as transport media ,then it was homogenized and inoculated in brain heart agar supplemented with Skirros’s supplement (Vancomycin, Polymyxin B sulphate, Trimethoprim lactate )and sheep or horse blood and incubated for 5-7 days under microaerophllic condition (156 ) campy pack systems.(34) 26 The organisms were identified by colonial morphology, gram stain and biochemical tests (urease, catalase and oxidase ). 2. 9.4 Identification of the isolates: 2 .9.4.1 Colonial morphology The significant growth of colonies were examined morphologically for size, Consistency, convex and ability to haemolysis . 2.9.4.2 Gram staining : The gram staining reaction used to help identify pathogens in specimens and cultures by their gram reaction (gram positive or gram negative ) and morphology .(157). Gram stain used in routine identification , the bacteria film fixed and stained with triphenyl methane dye basic dye such as crystal violet treatment with iodine solution and subsequently treated with alcohol, those bacteria which retain the dye are gram positive and those varieties of bacteria which loose the dye are gram-negative (3,34,157).Decolorized cells were stained by counter stain such as safranin red . The organisms were smeared in clean slid. The smears were allowed to dry in air and then fixed by gentle flaming. The slides were placed on the staining rack and flooded with crystal violet stain for one minute, Washed rapidly with clean tap water, covered with lugol`s iodine for one minute , Washed rapidly with clean tap water .All the smears decolorized rapidly with alcohol (few second ) and wash immediately with clean tap water ,The smears covered with counter stain neutral red for one minute. The stain was washed with clean tap water. The slides were placed in the slides rack for the smear to air dry ,Then the smears were examined microscopically using oil immersion objective and the results reported The organisms were gram negative bacilli . 2.9.4.3 Urease test Testing of urease enzyme activity is important to differentiating the urease producers bacteria. The test organism is cultured in medium which contains urea and the indicator phenol red . when the strain is urease producing the enzyme will break down the urea by hydrolysis to give ammonia and carbon dioxide. 27 With the release of ammonia medium change to alkaline as shown by change in colour of indicator to pink colour(157) In this work some colonies from each isolate were emulsified in 1 ml of urea reagent with phenol red in sterile tube, the organism which were urease producer will hydrolyze the urea to give ammonia and change the PH to alkaline to produce pink colour. 2.9.4.4 Catalase test : This demonstrates the presence of catalase enzyme that catalyses oxygen from hydrogen peroxide (157).and used to differentiate those bacteria that produce the catalase enzyme(157). A colony was picked by platinum loop or wooden stick and placed in 3% hydrogen peroxide solution in sterile tube Catalase enzyme acts as a catalyst in the break down of hydrogen peroxide to oxygen and water with immediate effervescence occurred which indicated positive result. 2.9.4.5 Oxidase test: This test depends on presence in bacteria of certain oxidases that will catalyze the transport of electrons between electron donors in the bacteria and a redox dyetetramethyl-p-phenylene-diamine. The dye is reduced to deep purple color(164). The isolates were smeared in oxidase reagent strip the phenylene-diamine in the reagent oxidized to deep purple color(157). 2.10 Sensitivity test : Laboratory antimicrobial sensitivity testing can be performed using The dilution technique The disc diffusion technique. In this work the two methods were used . 2.10.1 Inoculums’ preparation: H. pylori strain from gastric biopsy specimens were isolated on brain heart agar and stored at - 80 0C in glycerol media (Brain heart broth with 25% glycerol). The isolate were incubated in brain heart agar supplemented with 10% horse blood (158) for 48h at 37oC under microaerophilic condition ,produced as described above. Given the importance of inoculum homogeneity (158,159), cellular viability was 28 controlled microscopically by morphological observation with gram stain, cultures were always used after 48h of incubation when they generally didn't present coccoid forms(160) Suspensions were prepared in sterile normal saline to an opacity of McFarland standard (ca109cFU/ml).(158.161). 2.10.2. Disc diffusion method : Disc diffusion techniques are used by most laboratories to test routinely for antimicrobial sensitivity. A disk of blotting paper is impregnated with a known volume and appropriate concentration of antimicrobial. not more than six discs should be tested on a single plate to avoid fusion of inhibition zones to each other. Modified Kirby-Bauer sensitivity testing technique was used Mueller Hinton sensitivity testing agar prepared and sterilized and cooled then treated with horse serum and poured in sterile Petri dishes to depth of 4mm. The prepared media was solidify and dried (162). The prepared inoculums were inoculated in the media with sterile loop. The antimicrobial discs (Amoxicillin, Claritheromycin, Metronidazole, Tetracycline). Were picked by sterile forceps and places on the surface of the inoculated media and pressed lightly by the forceps to make contact with media to allow the antimicrobial to diffuse from the disc to the media . The plates ware incubated at 370C for 2-3 dayes under microaerophilic condition. (Campy-pak system).The culture was examined for zones of inhibition of bacterial growth around the respective disks. 2.10.4 Agar dilution method: The principle of the agar plate dilution method is the inhibition of growth on the surface of the agar by the antimicrobial agent (plant extract) incorporated into the medium. The organisms tested were prepared in sterile normal saline to an opacity of McFarland standard (ca109cFU/ml).(158,161). A loop full of the diluted culture is spotted with a standard loop that delivers 0.001ml on the surface of the media . Sterile screw cap tubes were numbered .All the following steps were cared out using aseptic technique. 1ml of Commiphora myrrh extract was added to 10 ml of methanol as the first tube and 10ml of sterile distilled water was added to all other tube. 29 10 ml transferred from the first tube to the second tube and mixed well with separate pipette and transferred 10 ml to the third tube. The dilution was continued in this manner to tube number 5and the pipettes changed between tube to tube to prevent carry over of extract on the external surface of the pipette .10 ml removed from tube 6 and discarded . Tube 6 which served as a control, no Commiphora added to it. Muller-Hinton media prepared in dabble concentration for amount of the media to 20 ml of D.W only 10 ml were used and autoclaved and cooled and supplemented with horse serum and the diluted extract added to it , mixed and transferred to the plate. After one drop of the suspension transferred to the plate .Incubated at 370C for two days and the result observed by growth or no growth The highest dilution without growth is the minimum inhibitory concentration 2.11 Data analysis: The data collected was analyzed using statistical package for Social Science for Personal Computer (SPSS/PC). Difference was considered significant at P value <0,05 and 95% Confidence Interval . 30 Results Hundred Specimens of antrum biopsy were taken by physician from Sudanese patients with Peptic ulcer disease who attended during the period October 2006November 2007 3.1 Demographic features of study population:3.1.1 Gender And Age : Demographic features of the patients included in the study 52 female and 48. (fig 1) and age ranged between 19 – 70 years which as classified in the study to be > 40 =64% and <40 =36 % .(Table 1) . 3.1.2 Residence distribution:Most of the patients were from Khartoum state 62%, 14% from the North, 5% from the East Sudan and from the West Sudan 4% and 10 from Southern Sudan and from Central Sudan 5% .( fig 2) 3.1.3 Occupation distribution: The study population distributed according to there jobs to 32 manual workers, 31 house wives and 15 students , 6 farmers and 16 other jobs (Doctors ,Employers ,Engineers and Teachers). (fig 3). 3.2 Endoscopy results: The study population included 15 Gastritis, 4 Duodenitis, 32 both Gastritis & Duodenitis, 14 Duodenum ulcer ,5 Gastric ulcer and 2 with Esophagus variesis and 5 with both Gastric ulcer & Duodenum ulcer ,2 were Gastric hernia 8 with both Gastritis & Duodenum ulcer and 3 with Gastritis & Esophagitis & duodenum ulcer 7 were with Gastritis and esophagitis .(fig 4) [ 3.3 Rapid urease test results: In the hundred specimen 86% were showed positive rapid urease test and 14% 31 negative for urease test. (Table 2). 3. 4 Culture results: Sixty showed positive growth and fourty were negative growth .(Table 3) 60 of urease positive showed positive growth and 26 no growth, none of negative urease showed growth (table 4). The growth rate in women was higher than in men 53.4%: 46.6 % respectively (table 5) In the study population there were high positive growth in house wife 23, manual workers 19 , 7 students and 5 farmers and 6 others ( table 6) . Positive culture growth were high in Khartoum state (Table 7). Endoscopy findings showed high growth rate in Gastritis & duodenitis 21 and duodenum ulcer 9 and 7 and Gastritis duodenal ulcer and gastritis 5and 4 Gastric ulcer & duodenal ulcer And 3 duodenitis and 3 gastric ulcer and the same number Gastritis & esophagitis .& duodenal ulcer and 2 Gastritis & gastric ulcer and 2 Gastritis & esophagitis . and one esophagus varaesis and there were no growth in esophagitis . nor in gastric hernia Fig (5). 3.5 Sensitivity test results: 3.5.1 Antibiotic disk results: The susceptibility tests for sixty H .pylori isolates were determined by the Kirby Bauer disk diffusion technique against(Amoxicillin, Metronidazole, Tetracycline ,Clarithromycin ). The sensitivity assessment showed high resistance rate in Clarithromycin and Metronidazale and high sensitivity to Amoxicillin and then to Tetracycline (fig 6, 7, 8, 9). 3.5.2 Plant antimicrobial results: The plant antimicrobial activity was determined by agar dilution method to plant extract against H. pylori isolates and which showed high sensitivity 100% in dilution one (1/20) and 90% in dilution two (1/40) and in the third dilution (1/80) the sensitivity 50% (30 out of 60) and the sensitivity decrease in dilution four to (1/160) 20% (fig10,11,12,13). 32 Fig (1) Gender distribution and percentage in study population. 33 Table (1) Age distribution and percentage in study population. Age >40 Number of patient Percentage 64 64.0% <40 36 36.0% Total 100 100.0% 34 Fig (2) Distribution of the study population according to their residence 35 Fig (3) Distribution of the study population according to their Occupation . 36 10 0 Frequency Endoscopy INDOSCOP 40 30 20 it eg ph se O & ric tis st i tri ga ag as & G s ph e iti tr os as al & G s en iti tr od i as du en G od tis tri du den & as o G du tis is r& tri ce aes as ul r G c va tri s u as G ag ph ia so rn oe ha c iri r st ce ul r ga c ce iri ul st ga num e od tis du gi ha sp s oe iti en od du s i rit st ga Endoscopy INDOSCOP Fig (4) Distribution of study population according to Endoscopy results 37 Table (2) Results of Rapid urease test in hundred GIT biopsy Number of biopsy Rapid urease test positive negative Total Percentage 86 % 14 % 100 % 86 14 100 38 Table (3) Percentage of the growth in one hundred GIT biopsy Culture Number of biopsy Percentage Growth 60 60 % No growth 40 40 % 100 100 % Total 39 Table (4) Relation ship between the growth and urease results. Culture growth no growth Total Rapid urease test positive negative 60 0 Total 26 14 40 % 86 14 100 % 40 60 % Table (5) Relation between Gender In the study population and growth. Gender Male Female Total Growth 56 % 63 % 60 % Culture No growth 44 % 37 % 40 % 41 Total 48 52 100 Table (6) Relation ship between Occupation in the study population and growth of H. pylori . Occupation House-wife Manual workers Students Farmers Others Total Culture Growth 74% 59% 47% 83% 39% 60% 42 No growth 26% 41% 53% 17% 62% 40% Total 31 3 15 6 16 100 Table (7) Relation ship between residence of the study population and growth. Residence Khartoum North Sudan East Sudan West Sudan South Sudan Central Sudan Total Culture no growth growth 60 % 40 % 64 % 36 % 40 % 60 % 100 % 0 % 60 % 40 % 40 % 60 % 60 % 40 % 43 Total 62 14 5 4 10 5 100 grow th no grow th 0 Count 30 20 CULTURE 10 it eg ph se O ic & r t ti s as gi g tri a as s & ph G i e t os al tri n & as G iti s ode i n u tr as s d ode G i u t en tri & d o d as u G ti s &d i s tri cer es l as ra G ic u va s tr as gu G ha ia p n s o har oe c r iri ce r st l ga ic u l ce u ir st m ga enu od i tis du ag h sp is oe nit e od du tis ri st ga Endoscopy INDOSCOP Fig (5) Relation ship between endoscopy finding of the study population and growth. 44 Fig (6) Sensitivity and resistance of H. pylori to Clarithromycin. 45 Fig (7) Sensitivity and resistance of H. pylori to Metronidazole . 46 Fig (8) Sensitivity and resistance of H. pylori to Amoxicillin. 47 Fig (9) Sensitivity and resistance of H. pylori to Tetracycline. 48 Fig (10) Sensitivity and resistance of H. pylori to Commiphora myrrh extract in dilution one (1/20) 49 Fig (11) Sensitivity and resistance of H. pylori to Commiphora myrrh extract in dilution tow (1/40) 50 Fig (12) Sensitivity and resistance of H. pylori to Commiphora myrrh extract in dilution three (1/80). 51 Fig (13 ) Sensitivity and resistance of H. pylori to Commiphora myrrh extract in dilution four(1/160) . 52 Discussion In the present study the prevalence of H .pylori infection observed was higher in women than men, this confirmed what found in the studies that were done in Khartoum teaching hospital and Academy Charity teaching hospital, Soba hospital and Ibin Sina hospital (3,163,164) and similar to that reported in the study done in Ninth people`s Hospital of Shanghai (165). In this study the prevalence of H. pylori infection was high among elderly as it was observed in the study done by Gunaid et al (166) which found that there was significant difference in prevalence of H .pylori infection between age group 41-75 year (90%) and age group 16 -36 years (75%) (166,167) and similar to study done by Duggan and Duggan (2006)(13) found that H . pylori colonization rates remained high in the elderly and also in agreement with the study done in King Faisal University (168). In this study, although most of study population came from Khartoum state but originally were from the rural areas of Khartoum. This agree with the study that found urbanization and the crowded living conditions of expanding cities might result in decline in hygiene for large sections of the population . This phenomenon may be associated with a concomitant rise in exposure and prevalence of H . pylori infection (166,168 ). And also in agreement with the study which it found that 60% of the patients were originally from rural areas (3).This may explain that H .pylori infection is common in poor areas and another study that showed the infection in rural population had been higher than that of an urban population (169) . In this study, most of population are manual workers (32%) , 31% were house wives and 15 % students , 6% farmers and all other jobs (Doctors ,Employers , Engineers and Teachers) were16%.. In this study the sensitivity of urease test was high 86% and the specificity compared with the culture as gold standard method was 71.4% . The high sensitivity is similar to that in study done in Sana`a (166) and also agree with the study done in Ibn Sina Hospital (170) and similar to the study that was done by Thillanyagam et al who was found that the sensitivity was 83% (171) and slightly high from that in study done in South Africa 71% (172). This sensitivity did not confirm the higher sensitivity reported by Marshall etal 1987 which was found to be 99% (173) . 53 In This study there were 32 cases of both Gastritis & Duodenitis and 15 Gastritis, 4Duodenitis, and, 14 were Duodenum ulcer and 5 with Gastric ulcer and 2 with Esophagus variesis and 5 with both Gastric ulcer & Duodenum ulcer and 2 were Gastric hernia 8 with both Gastritis & Duodenum ulcer and 3 with Gastritis & Esophagitis & duodenum ulcer 7 were with Gastritis and esophagitis This showed that the endoscopic appearance of ulcer and inflammation is acute and active in most of the patients which agreed with the studies done in Soba Hospital and Khartoum Teaching Hospital and Academe hospital (3, 163) . In this study susceptibility of H . pylori to antimicrobials among Sudanese patients with peptic ulcer disease was determined by agar dilution method for the plant Commiphora myrrh and disk diffusion to antibiotic disks ( Metronidazole ,Amoxicillin, Tetracycline, Clarithromycin). Metronidazole: The resistance of H. pylori to Metronidazole varies from population to population (168,174,175,176) It is highest in the developing and lowest in developed countries (174,175,177) .In this study, the prevalence of Metronidazole resistant H .pylori isolates was 61.7 %; it is similar to the study done In Sudan at Ibn Sina Hospital which found the resistance rate was 61% (170). This high resistance rate is similar to finding in the study done in urban Asia population 62% (178) also the results of the present study agreed with the results of study done in Japan which observed that a higher prevalence of Metronidazole -resistant strains is seen in the western or southern regions although it was very rare in northern region of Japan and in Japan generally; this was explained differ by the close proximity of these regions to other Asian countries, which have a high prevalence of Metronidazole -resistant H. pylori. South and West Japan are much closer to these countries than North Japan (179). It also agreed with the results of the study done in King Fahd Hospital of university Khobar which found high prevalence of Metronidazole -resistant H. pylori(180) and it was slight high than resistance rate reported from Bahrain ,Gulf region which found those who were infected by resistant strains to Metronidazole were 57% (181.) Resistance of H .pylori to Metronedazole is related to the previous exposre to the drug (174,175,182) It has been suggested that the high prevalence rate of Metronidazole resistant H. pylori in women may be due to it use in the treatment of vaginal infections such as trichomoniasis and Gardnerella and as prophylaxis in uterine surgery (182) .Previous use for the treatment of amoebiasis and other diarrheal diseases and possible increased use for protozoal and anaerobic infection . 54 Clarithromicin The likelihood of antibiotic resistance varies by geographical Region.. Additionally, prior use of clarithromycin or metronidazole for any infection, has been shown to increase the likelihood of H pylori resistance to these agents(183). Clarithromycin resistance varies from less than 5% in southern parts of Europe to greater than 20% in northern Europe(195) to as high as 80% in some developing countries. (184) which was agreed with the finding of study that showed high prevalence of Clarithromycin- resistant H .pylori ,also agreed with the study done in Japan(179) and that one done in Singapore (185) . Amoxicillin Antibiotics. Amoxicillin, a semi-synthetic penicillin, is an effective antibiotic for H. pylori infection. The frequency of amoxicillin resistant H. pylori organisms is low. The drug rapidly accumulates in anural mucosa via systemic circulation. Its antimicrobial activity against H. pylori depends on the pH level; the minimal inhibitory concentration (MIC) decreases as the pH increases. (186). The highest prevalence of sensitivity detected was against Clavunlinated Amoxicillin which agreed with the study done in the Gemelli hospital of Rome that showed the highest sensitivity rate in Amoxicillin (187) and also with the study done in Japan (179) and it was higher than that of study done in United states which found the resistance rate to Amoxicillin 1.4% (188).Data collected in 1998- 2002 found the reissuance rate was 9 %(189). It appears that Amoxicillin resistance have remained relitatively stable .and highest from the study done in India which found that 0.9% of isolates were resistant to Amoxicillin (190).Reports of resistance to amoxicillin have been extremely rare.(191,192). Tetracycline Helicobacter pylori resistance to Tetracycline was not reported until 1996., when Midolo and colleagues reported Tetracycline resistant strains from Australia (193,194), and the studies done in Italy 1997 (193,195 ) that found 8% of strain were Tetracycline resistant In this study the prevalence of H . pylori susceptible strain were 61.7% this high sensitivity is slightly higher than that study done in Ninth people`s Hospital of Shanghai that were found the sensitivity was 58% (193) and from the study done in Douala General Hospital, Cameroon which found that Tetracycline susceptibility rates 55 were 56% (196). This prevalence of high H . pylori susceptibility rate were lowest from the rate in study done in India which was found all the isolates were sensitive to Tetracycline (190).. Antibiotic treatment of H. pylori infection is not without risk. Antibiotic therapy can lead to the development of pseudomembranous colitis, a potentially severe infection caused by Clostridium difficile. In addition, antibiotics frequently enable the overgrowth of Candida albicans, which can result in vaginitis, gastrointestinal disturbances, or other complaints. Moreover, antibiotic treatment could lead to the overgrowth of antibiotic-resistant strains of H. pylori, making further attempts at eradication more difficult. (32). Investigations into plant materials as alternative sources of antimicrobials have become more common over the past few years, due to the increased rate of development of antibiotic resistant organisms. New strategies to combat infection are also being sought and one such strategy is the use of ‘anti-adhesive’ molecules, targeting the primary step of infection - adhesion of the organism to host tissue (197,198). In this study, H. pylori showed high sensitivity rate to extract of Commiphora myrrh which were 100% in dilution one ,90% for dilution two ,60%dilution three and 20% for dilution four that was shown as the MIC at dilution one1/20. This high sensitivity was similar to other studies done on other bacteria and microorganisms . The only one study done on effect on gastric ulcers done by Al-Harbi and et al (1994) in rats who was investigated the extract of myrrh for its ability to protect the stomach lining against laboratory-induced ulcers in rodents. They found that pre-treatment with myrrh resulted in a dose-dependent protection against ulceration (199). 56 Conclusion The high rate of resistance in our patients would suggest that sensitivity testing to alternative treatment against Helicobacter pylori is necessary. Commiphora myrrh has wide-spectrum antimicrobial activity and it can investigated as alternative treatment against Helicobacter pylori. 57 Recommendation Due to the high rate of resistance to available anti-infective agents, Commiphora myrrh can be examined as an alternative treatment on H. pylori. 58 References 1/ Mahadi A.A. (1999). Helicobacter pylori and peptic ulcer diseases. Thesis for M.Sc. Khartom University Faculty of Medicine 2/ Shearman, D. J.C. Disease of the alimentary tract and pancreas.ln: Edwareds CRW.Bouchier IAD, Haslett C and Chilvers ER (1995)(ed) Davidson`s principles and practice of medicine. Edinburgh ,Churchill Living stone 426-435 . 3/ Mohamed, Y. H. (2003).Helicobacter pylori sensitivity to Antibiotic in the Sudan. Thesis for M.Pharm. Faculty of pharmacy. 4/ Misiwize,J.d,and Pounder,R.E. Peptic ulcer in Oxford Text-book of medicine, Ediat and publisher volume 1:12 – 68. 5/ Elbagir M.,Ahmed, K.(1988) Duodenal ulcer in Sudan . Sudan medical Journal; 24:14: 1-2. 6/ Fedail, S.S., Arbab, B. M., Homaeida, M. and Ghandour, M. Z. (1983) Upper gastrointestinal fibrotic endoscopy experience in the Sudan. Lancet; 1879: 9. 7/ Kheir, M.M., Fedail, S.S.and Elkadarou, A. G. (1998) Seasonal variations in the incidence of endoscopically proved duodenal ulcer in Sudan. Saudi J. gastroenterology; 4: 17-19. 8/ Taylor, D. N. a nd Paarsonnet, J. (1995)The epidemiology and natural history of H. pylori infection. In Blaster, M, J. Smith, P. D. Rardin , J.I Greenberg, HB. Geurant, R. L. Infection of the GIT New York Raven press, 551-564 9/ McNulty, C. A., Dent, J. C., UFF. J., Gear, M. W.,and Wilkinson, S (1989). Detection of campylobacter pylori by the biopsy urease test. an assessment in 1445 patients gut, 30:1058-1062. 10/ Katelaris, P.H., Tippett, G.H., Norbu, P., Brennan, R. and Farthing, M.J. (1992) Dyspepsia Helicobacter pylori and peptic ulcer in a randomly selected population in India. Gut; 33: 1462-1466. 59 11/ Misra V, Misra S.P., Dwivedi, M. and Singlh, P.A. (1997), Point Prevalence of peptic ulcer and gastric histology in healthy Indians with Helicobacter pylori infection. American Journal of Gastroenterology ;92:1487-1490 . 12/ Vaiva, D., Miglioli, M. and Mule, P. (1994). Prevalence of peptic ulcer in Helicobacter pylori positive blood donors. Gut ; 35: 309-312. 13/ John, M., Duggan and Anne, E. D. (2006) The possible causes of the pandemic of peptic ulcer in the latte 19 th an early 20th century MJA.;185 nummber 11/12. 4/18:667 9. 14/ Marshall, B. J. and Warren, R. (1984).Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulcer. Lancet :1311-1315. 15/ Baron, J. H.and Sonnenberg, A..(2002).Alimentary diseases in the poor and middle class in London 1773-1815 and in New York poor 1797-1818 .Aliment Pharmacol ther;.16.1709 – 1714. 16/ Cullen, D. J., Hawkey, G. M.and Green Wood, D.C. (1997), Peptic ulcer bleeding in the eldaerly. Relative roles of Helicobacter pylori and non-steroidal antiinflammatory drugs. Gut ; 41:459-462. 17/ Rosentock, S., Jorgenson, T. and Bonnevie, O. (2003).Risk factors for peptic ulcer disease apopulation based prospective cohort study comprising 2416 Danish adults. Gut ; 52:186-195. 18/ Lilienfeld, A. M. (1976).Foundations of epidemiology 1sted New York, oxford university press. 19/ Calam, J. (1998). Gastritis and peptic ulcer .Medicine International; July/Aug :1115 . 20/ Delia, S., Timothy, F.(2006). Risk of serious NSAID-related gastrointestinal events during long-term exposure a systemic review MJA ; 185 : 9.6 . 21/ Smueda., K. H.,Youshid, O. F., Kanrai,T.I ., Kenole, N.,Kato,X., Moata, M. (1998) Virulence factors,VaCA and Cag A are commonly positive in H. pylori isolates in Japan. Gut ; 42 : 338-343 60 22/ Goldstein, J.L., Siliverstein, F.E., Agrawal, N.M. (2000).Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J G astroentrol ; 95:1681-1690. 23/ Singh,G.and Triadafilopoulos, G.(1999). Epidemiology of NSAID induced gastrointestinal complications J Rheumatol ; Suppl 26:18-24. 24/ Doll, R., Peto, R., Wheatley, K. (1994). Mortality in relation to smoking ,40 years` observation on male British doctors. BMJ; 309:901-911. 25/ Doll, R., Peto, R., Hall, E. (1994).Mortality in relation to consumption of alcohol: 13years`observation on male British doctors.BMJ ; 309:911-918. 26/ Aldoori, W.H., Giovannucci, E.L., Stampfer, M.J. (1997). A prospective study of alcohol ,smoking, caffeine and the risk of duodenal ulcer in men . Epidemiology;8:420424. 27/ Katschinski, B.D.,.Logan, R. F., Edmonal, M. (1990). Duodenal ulcer and refined carbohydrate intake :a case-control study assessing dietary fiber and refined sugar intake. Gut ; 31:993-996. 28/ Sonnenberg. A. (1986) Dietary salt and gastric ulcer gut; 27:1138-1142. 29/ Raiha, I., Hkaprio, J. (1998) Lifestyle, stress. and genes in peptic ulcer disease: a nationwide twin cohort study of .Arch intern Med ;158:698-704. 30/ Malaty, H. M., Graham, D.I. and et al. (2000) Are genetic influences on peptic ulcer dependent or independent of genetic factors for Helicobacter pylori infection. Arch intern Med.; 160:105-109. 31/ Malaty H. M., Engastr, L. and Pedersen N.L. (1994). Helicobacter pylori infection. genetic and environmental influences. A study of twins. Arch intern Med.;120:982-986 32/ Alan, R. and Gaby, M. D. (2001) Helicobacter pylori Eradication: Are there Alternatives to Antibiotics? Alternative Medicine Review..volume 6;4:355-366 34/ Robert, J. O. (2005 ) Helicobacter.Toply and Wilson Medical microbiology 61; 1564-1590. 35/ Warren, J. R. and Marshall., B. J. (1984).Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1:1311-1315 61 36/ Goodwin, C.S. and Armstrong, J. A. (1989) Transfer of Campylobacter pylori and Campylobacter mustelae to Helicobacter gen. Nov. as Helicobacter pylori Comb. Nov. and Helicobacter mustelae. Comb. Nov. respectively .Int. J. Syst Bacteriol.;39:397405 37/ Vandamme, .P. and Falsen., E. (1991) Revision of Campylobacter. Helicobacter and wolinella taxonomy .emendation of generic descriptions and proposal of Arcobacter Gen. Nov. Int J Syst Bacteriol.;41:81-103. 38/ Medizinischen Fakulatat ,Ernst-Moriz-Arndt (2003). Molecular analysis of Helicobacter pylori-associated gastric inflammation in chronically infected and immune mice. Institut of immunology and transfusion medizin Greifwald university. 39/ Marshall, B. J., Armstrong, J.A., McGechie, D..B. and Glancy, R. J. (1985). Attempt to fulfill Koch's postulates for pyloric Campylobacter. The Medical Journal of Australia ; 15;142(8):436-439. 40/ Morris, A. and Nicholson, G. (1987), Ingestion of Campylobacter pyloridis causes gastritis and raised fasting gastric pH. American Journal of Gastroenterology ;82(3):192-199. 41/Warren, J. R.and Marshall, B. J (1983). Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet; 4;1(8336):1273-1275. 42/Chan, W.Y., Hui, P.K., Leung, K.M., Chow, J., Kwok, F.and Ng, C.S. (1994), Coccid forms of Helicobacter pylori in the human stomach. American Journal of Clinical Pathology ; 102(4):503-507. 43/ Tomb, J.F., White, O., Kerlavage, A.R., Clayton, R.A., Sutton, G.G., Fleischmann, R.D., Ketchum, K.A., Klenk, H.P., Gill, S., Dougherty, B.A., Nelson, K., Quackenbush, J., Zhou, L., Kirkness, E. F., Peterson, S., Loftus, B., Richardson, D., Dodson, R., Khalak, H.G., Glodek, A., Mc Kenney, K., Fitzegerald, L.M., Lee, N., Adams, M.D., Venter, J.C. and et al. (1997 ) The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature:7;388(6642):539-547. . 44/ Mitchell, H..M. (1999) The Epidemiology of Helicobacter pylori (in Westblom, T.U., Czinn S.J., Nedrud, J.G., Gastro duodenal disease and Helicobacter pylori). Current Topics in Microbiology and Immunology 241: 11-30 45/ Sean, O. Hynes, John A. Ferris Bogumila Szponar, T., Wadström, J.G., Fox 62 J., O’Rourke, L., Larsson, E.,Yaquian, Å., Ljungh, M., Clyne, L.P., Andersen, and Anthony, P. M. (2004). Comparative Chemical and Biological Characterization of the Lipopolysaccharides of Gastric and Enterohepatic Helicobacter. Blackwell Publishing Ltd, Helicobacter; 9: 313-323. 46/ Andersen, L P., Boye, K., Blom, J., Holck. S., Nørgaard, A. and Elsborg, L. (1999) Characterization of a culturable ‘Gastrospirillum hominis’ (Helicobacter heilmannii) strain isolated from human gastric mucosa. J Clin Microbiol; 37:1069-1076 . 47/ Holck, S., Ingeholm, P. and Blom, J. (1997). The histopathology of human gastric mucosa inhabited by Helicobacter heilmannii-like (Gastrospirillum hominis) organisms, including the first culturable case. APMIS ;105:746-56. 48/ Dunn, B.E, Cohen, H.and Blaser, M.J. (1997) Helicobacter pylori. Clin Microbiol Rev 10:720-741. 49/ Wotherspoon, A.C., Doglioni, C.and Diss, T.C. (1993). Regression of primary lowgrade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori .Lancet; 342:575-7. 50/ Wadström, T.( 2000) Helicobacter in extragastric intestinal and liver disease. Acta Gastroenterol Belg ; 63:393-400. 51/ Solnick, J.V. and Schauer. D. B. (2001) Emergence of diverse Helicobacter species in the pathogenesis of gastric and enterohepatic diseases. Clin Microbiol Rev; 14:59-97. 52/ Haque,M .Harai,Y. (1996) Lipid profile of Helicobacter spp presence of cholesteryl glucoside as acharacteristic feature.J Bacteriol. 178:2065-2070. 53/ Elmer, W., Koneman, S. D., Allen, W. M., Janda, P. C., Schreckenberger, W. C.,Winn,Jr. Curved gram-negative bacilli and oxidase-positive fermenters :Campylobacters and Vibrinaceae Color atlas and textbook of diagnostic microbiology ; fourth edition. 256-258. 54/ Dunn, B.E., Campbell, G.P., Perez-Perez, G.I. and Blaser, M.J.(1990)Purification and characterization of urease from Helicobacter pylori. The Journal of Biological Chemistry; Jun 5;265(16):9464-9469. 63 55/ Mai, U.E., Perez-Perez, G.I., Allen, J.B., Wahl, S.M., Blaser, M.J., Smith, P.D (Feb1992 )Surface proteins from Helicobacter pylori exhibit chemotactic activity for human leukocytes and are present in gastric mucosa. Journal of Experimental Medicine 1;175(2):517-525. 56/ Dunn, B.E., Vakil, N.B., Schneider, B.G., Miller, M.M., Zitzer, J.B., Peutz, T. and Phadnis, S.H. (1997) Localization of Helicobacter pylori urease and heat shock protein in human gastric biopsies. Infection and Immunity Apr 65(4):1181-1188. 57/ Marais, A. (1999) Microbiology of Helicobacter pylori (in Westblom, T.U., Czinn, S. J Nedrud, J.G., Gastroduodenal disease and Helicobacter pylori). Current Topics in Microbiology and Immunology, 241: 103-122 . 58/ Karttunen, R., Andersson, G., Poiikonen, K., Kosunen, T. U., Karttunen, T., Juutinen, K. and Niemela, S. (1990). Helicobacter pylori induces lymphocyte activation in peripheral blood cultures. Clinical and Experimental Immunology Dec;82(3):485- 488. 59/ Tommaso, A., Xiang, Z., Bugnoli, M., Pileri, P., Figura, N., Bayeli, P. F Rappuoli, R., Abrignani, S. and Magistris, M. T., (1995) Helicobacter pylori-specific CD4+ Tcell clones from peripheral blood and gastric biopsies. Infection and Immunity; Mar 63(3):1102-1106. 60/ Maeda, S., Akanuma, M., Mitsuno, Y., Hirata, Y., Ogura, K., Yoshida, H Shiratori, Y., Omata, M., (2001 ) Distinct mechanism of Helicobacter pylori-mediated NFkappa B activation between gastric cancer cells and monocytic cells. Journal of Biological Chemistry 30;276(48):44856-44864. 61/ Keates, S., Hitti, Y.S., Upton, M.and Kelly, C.P. (1997 ). Helicobacter pylori infection activate NF-kappa B in gastric epithelial cells. Gastroenterology; Oct 113(4):1099-1109. 62/ Noach, L.A., Bosma, N.B., Jansen, J., Hoek, F.J., van Deventer, S.J.and Tytgat, G.N (1994).Mucosal tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-8. production in patients with Helicobacter pylori infection. Scandinavian Journal, of Gastroenterology; 29(5):425-429. 63/ Nielsen, H.and Andersen, L.P., (1992) Activation of human phagocyte oxidative metabolism by Helicobacter pylori. Gastroenterology Dec;103(6):1747-1753. 64 64/ Noorgaard, A., Andersen, L.P., Nielsen, H., (1995). Neutrophil degranulation by Helicobacter pylori proteins. Gut Mar;36(3):354-357. 65/ Appelmelk, B.J., Simoons-Smit, I., Negrini, R., Moran, A.P., Aspinall, G.O., Forte J.G., De Vries, T., Quan, H., Verboom, T., Maaskant, J.J., Ghiara, P., Kuipers, E.J., Bloemena, E., Tadema, T.M., Townsend, R.R., Tyagarajan, K., Crothers, J. M. Jr., Monteiro, M.A., Savio, A.and Graaff, J. (1996). Potential role of molecular mimicry between Helicobacter pylori lipopolysaccharide and host Lewis blood group antigens in autoimmunity. Infection and Immunity ; Jun;64(6):2031-2040. 66/ Claeys, D., Faller, G., Appelmelk, B.J., Negrini, R.and Kirchner, T. (1998).The gastric H+,K+-ATPase is a major autoantigen in chronic Helicobacter pylori gastritis with body mucosa atrophy. Gastroenterology; 1 Aug;115(2):340-347. 67/ Peterson, W.L., Barnett, C.C., Evans, D.J.Jr., Feldman, M., Carmody, T. Richardson, C., Walsh, J.and Graham, D.Y., (1993) Acid secretion and serum gastrin in normal subjects and patients with duodenal ulcer: the role of Helicobacter pylori . American Journal of Gastroenterology Dec;88(12):2038-2043. 68/ Peterson, W.L., (1991).Helicobacter pylori and peptic ulcer disease. New England Journal of Medicine ;Apr 11;324(15):1043-1048. 69/ Hui, P.K., Chan, W.Y., Cheung, P.S., Chan, J. K. and Ng, C.S., (1992) Pathologic changes of gastric mucosa colonized by Helicobacter pylori. Human Pathology May;23(5):548-556. 70/ Kuipers, E.J., Thijs, J.C., Festen, H.P., (1995). The prevalence of Helicobacter pylori in peptic ulcer disease. Alimentary Pharmacology & Therapeutics;9 Suppl 2:5969. 71/ Rauws, E.A., Tytgat, G.N. (1990) Cure of duodenal ulcer associated with eradication of Helicobacter pylori. Lancet May 26;335(8700):1233-1235 . 72/ Graham, D.Y., Lew, G.M., Klein, P.D., Evans, D.G., Evans, D.J.Jr., Saeed, Z.A., Malaty, H.M. (1992) Effect of treatment of Helicobacter pylori infection on the longterm recurrence of gastric or duodenal ulcer. A randomized, controlled study. Annals of Internal Medicine May 1;116(9):705-708 . 73/ Correa, P., Haenszel, W., Cuello, C., Zavala, D., Fontham, E., Zarama, G., Tannenbaum, S., Collazos, T., Ruiz, B. (1990), Gastric precancerous process in a high risk population: cross-sectional studies. Cancer Research Aug 1;50(15):4731-4736. 65 74/ Kuipers, E.J., Uyterlinde, A.M., Pena, A.S., Roosendaal, R., Pals, G., Nelis, G.F., Festen, H.P., Meuwissen, S.G., Long-term sequelae of Helicobacter pylori gastritis Lancet Jun 1995 17;345(8964):1525-1528. 75/ Nomura, A., Stemmermann, G.N., Chyou, P.H., Kato, I., Perez-Perez, G.I., Blaser, M. J. (1991), Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. New England Journal of Medicine Oct 17;325(16):1132-1136. 76/ Parsonnet, J., Friedman, G.D., Vandersteen, D. P., Chang, Y., Vogelman, J.H Orentreich, N., Sibley, R. K. (1991), Helicobacter pylori infection and the risk of gastriccarcinoma. New England Journal of Medicine; Oct 17;325(16):1127-1131. 77/ Wotherspoon, A.C., Ortiz-Hidalgo, C., Falzon, M. R., Isaacson, P.G (1991). Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet Nov 9;338(8776):1175-1176. 78/ Wotherspoon, A.C., Doglioni, C., Diss, T.C., Pan, L., Moschini, A., De Boni, M. and Isaacson, P.G (1993)., Regression of primary low-grade B-cell gastric lymphoma of mucosaas- sociated lymphoid tissue type after eradication of Helicobacter pylori. Lancet Sep ; 4;342(8871):575-577. 79/ Hussell, T., Isaacson, P. G., Crabtree, J.E., Spencer, J. (1993) . The response of cells from low-grade B-cell gastric lymphomas of mucosa-associated lymphoid tissue to Helicobacter pylori. Lancet; Sep 4;342(8871):571-574. 80/ Hussell, T., Isaacson, P.G., Crabtree, J.E., Spencer, J. (1996). Helicobacter pylorispecific tumor-infiltrating T cells provide contact dependent help for the growth of malignant B cells in low-grade gastric lymphoma of mucosa-associated lymphoid tissue. The Journal of Pathology; Feb;178(2):122-127. 81/ Peter, M. F. and et al. (1994). Diagnosis of H. pylory its role in gastrointestinal disease; 52-54 . 82/ Han. S. W., Flamm .R. (1995). Transport and storage of Helicobacter pylori from gastric mucosal biopsies and clinical isolates Eur. J. Clin. Microbial Infect dis; 14:349352. 83/ Soltesz,V., Zeeberg, B. and Wadstrom, T. (1992). Optimal survival of Helicobacter pylori under various transport conditions. Clin Microbiol; 30:1453-1456. 66 84/ Vaira, D. and Vakil, N. (2002).The stool antigen test for detection of Helicobacter pylori after eradication therapy. Ann Intern Med; 136:280-287. 85/ Dent, C .A. and McNulty, J. c. (1988) Evaluation of a new selective medium for Campylobacter pylori .Eur J clin Microbial Infect; Des 7: 555-558. 86/ Marshall, B. J. and Warren, R. J. (1987). Rapid urease test in urine management of Campylobacter pylori- associated gastritis . AM.J Gastroentrol; 82.200-210. 87/Arvind, A. S. and Cook, R. S. (1988).One-minute endoscopy room test for Campylobacter. Lancet ; 1:704. 88/ Leodolter, A., Walle, K. and Malfetheiner, P. (2001). Current standard in the diagnosis of Helicobacter pylori infection .Dig Dis.;19:116-122. 89/ Clevel and clinic journal of medicine (2005) volume 72.supplement 2 may 90/ Goddard,A. F., Logan, R. P. (1997). Urea breath tests for detecting Helicobacter pylori. Aliment Pharmacol Ther; 11:641–649. 91/ Graham, D.Y. and Klein, P. D. (2000). Accurate diagnosis of Helicobacter pylori. 13Curea breath test. Gastroenterol Clin; North Am 29:885–893. 92/ Vaira, D. and Vakil, N. (2001). Blood, urine, stool, breath, money, and Helicobacter pylori. Gut; 48:287–289. 93/ Chey, W. D. and Fendrick, A. M. (2001) Noninvasive Helicobacter pylori testing for the “test-and-treat” strategy. A decision analysis to assess the effect of past infection on test choice. Ann Intern Med; 161:2129–2132. 94/ Cigna healthcar coverge posittion (H. Pylori tisting ) Subject Helicobacter Pylori 11/15/2007 : Coverage Position Number .0308. 95/ Islam, S., Weilert, F., Babington, R., Dickson, G. and Smith, A.C. (2005)Stool antigen testing for the diagnosis and confirmation of eradication of Helicobacter pylori infection: a prospective blinded trial. Intern Med J; Sep;35(9):526-9. 96/ Leodolter, A.and Vaira, D. (2003) European multi center validation trail of tow new non-invasive tests for detection of antibody to H. pylori ; urine-based ELISA and rapid urine test. Aliment. pharmacol Ther ;18;927-931. 67 97/ Luzza, F., Imeneo, .M. (2000) Evaluation of a commercial serological kit for detection of salivary immunoglobulin G to Helicobacter pylori a multicenter study .Eur gastroenterol Hepatol; 12:1117-1120. 98/Kato, M., and Asaka, M. (2000).Clinical usefulness of urine-based enzyme linked immunoabsorbent assay for detction of antibody to Helicobacter pylori acollaborative study in urine medical institutions in Japan. Helicobacter; 5:109-119. 99/ Kabir, s. (2001) .Detection of Helicobacter pilori in faeces by culture,PCR and enzyme immunoassay. J med microbiol; 50:1021-1029. 100/ Bell, S. J. and Chisholm, S. A. (2003) Evaluation of Helicobacter species in infammatory bowel disease. Aliment Pharmacol Ther; 18: 5: 481-486. 101/ Romero-Lopez. C. Owen .J.R .et al. (1993) Comparison of ureasecgene primer sequences for PCR -based ampliationn assay in identifying the gastric pathogen Helicobacter pylori .Mol Cell prbe;7:439-446 . 102/ Chisholm.S.A and Owen R.J. (2003).Development and application of anovel screening PCR assay for direct detection of Helicobacter heilmannii-like organisms in hilman gastric biopsies in Southaest England .Diag.Microbiol infect Dis;46:1-7. 103/ Hammar .M. and Tyszkiewicz, T. (1992) Rapid detection of Helicobacter pylori in gastric biopsy material by polympolymerase chain reaction. J Clin Microbiol; 30: 54-58. 104/ William.M.P. and Sercombe.J.C. (2000) The effect of Omeprazole dosing on the isolation of Helicobacter pylori from gastric aspirates. Amaricant Pharmacol Ther; 13: 1161-1169. 105/ Mihály, K..( 2007). Towards evidence based H. pylori eradication determination of Helicobacter pylori Clarithromycin resistance directly from gastric biopsies. ;1-9. 106/ Trebesius K..( 2000). Rapid and specific detection of Helicobacter pylori macrolide resistance in gastrictissue by fluorescent in situ hybridisation. GUT.; 46: 608-614. 107 Rüssmann H. (2001). Comparison of fluorescent in situ hybridization and conventional culturing fordetection of Helicobacter pylori in gastric biopsy specimens. J. Clin. Microbiol.; 39: 304-308. 108/ Arienne Z., Ables, I., Simon and Emily R. (2007) Update on Helicobacter pylori Treatment .American Family physician; 75: (3):352-358 109/ Lara LF, Cisneros G, Gurney M, Van ness M, Jarjoura D. and Moauro B. (2003) One-day quadruple therapy compared with 7-day triple therapy for Helicobacter pylori infection. Arch Intern Med; 163: 2079-84. 68 110/ Treiber, G., Wittig, J., Ammon, S, Walker S. V. Doorn, L.J. and Klotz, U. (2002) Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication: a randomized controlled trial (MACLOR study). Arch Intern Med; 162: 153-60. 111/ Richard, J., Saad and William D. C.Treatment of Helicobacter pylori Infection in 2006 112/ Howden, C.W. and Hunt, R.H. (1998) Guidelines for the management of Helicobacter pylori infection. Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol; 93: 2330-2338. 113/ Coelho, L.G., Leon-Barua, R.and Quigley, E.M. ( 2000). Latin-American Consensus Conference on Helicobacter pylori infection. Latin-American National Gastroenterological Societies affiliated with the Inter-American Association of Gastroenterology (AIGE). Am J Gastroenterol; 95: 26882691. 114/ . Ulmer, H.J., Beckerling,A.and Gatz, G.( 2003). Recent use of proton pump inhibitor-based triple therapies for the eradication of H pylori: a broad data review. Helicobacter; 8: 95-104. . 115/ Gisbert, J.P., Khorrami, S., Calvet, X. and Pajares, J.M.( 2003) Systematic review: Rabeprazolebased therapies in Helicobacter pylori eradication. Aliment Pharmacol Ther; 17: 751-764. 116/ Vallve, M., Vergara, M., Gisbert, JP, Calvet X. (2002) Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis. Aliment Pharmacol Ther;16:1149-1156. 117/ Buzas, G.M. and Jozan, J.( 2004) [Eradication of Helicobacter pylori infection in Europe: a meta-analysis based on congress abstracts, 1997-2002]. Orv Hetil; 145: 2035-2041. 118/ Malfertheiner, P., Megraud, F., O’Morain, C., Hungin, A., Jones, R., Axon, A., Graham, D.Y, Tytgat G.( 2002) Current concepts in the management of Helicobacter pylori infection—the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther;16:167-180. 119/ Fischbach LA, van Zanten S, Dickason J. (2004) Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies. Aliment Pharmacol Ther;20:1071-1082. 120/ Gene, E., Calvet, X., Azagra, R., Gisbert, J.P. (2003)Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta-analysis. Aliment Pharmacol Ther;17:1137-1143. 121/ Graham, D.Y., Belson, G., Abudayyeh, S., Osato, M.S., Dore, MP, El-Zimaity, HM. (2004) Twice daily (mid-day and evening) quadruple therapy for H. pylori infection in the United States. Dig Liver Dis;36:384-387. 122/ Calvet, X., Garcia, N., Lopez, T., Gisbert, JP, Gene, E., Roque, M.( 2000) A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther;14:603-609. 69 123/ Boer, S.Y., Meeberg, P.C., Siem, H. and Boer. W.A. (2003). Comparison of four-day and seven-day pantoprazole-based quadruple therapy as a routine treatment for Helicobacter pylori infection. Neth J Med; 61: 218-222. 124/ Lara, L.F., Cisneros, G., Gurney, M., Ness, M., Jarjoura, D., Moauro, B., Polen, A., Rutecki, G.and Whittier, F. (2003) One-day quadruple therapy compared with 7-day triple therapy for Helicobacter pylori infection. Arch Intern Med; 163: 2079-2084. 125/ Dore,.M.P. and.Leandro,G (2000)Effect of pretreatment antibiotic resistance to Metronidazole and Clarithromycin on outcome of Helicobacter pylori therapy .ameta-analytical Sci.;45:68-76 . 126/ Van Doorn,.L. J. Figueiredo, C..( 1998).Expanding allelic diversity of Helicobacter pylori vacA. J Clin Microbiol.;36:2597-2603. 127/ Heep,.A. M. and Kist. (2000).Secondary resistance among 554 isolates of Helicobacter pylori after failure of therapy. Eur J Clin Microbiol.;19:538-541 . 128/ Qasim, A, Sebastian, S., Thornton, O., Dobson, M., McLoughlin, R.and Buckley, M. (2005) Rifabutin- and furazolidone-based Helicobacter pylori eradication therapies after failure of standard first- and second-line eradication attempts in dyspepsia patients. Aliment Pharmacol Ther;21:91-96. 129/ Hojo, M., Miwa, H., Nagahara. A. and Sato, N. (2001) Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection. Scand J Gastroenterol;36:690-700. 130/ Bilardi, C., Dulbecco, P., Zentilin, P., Reglioni, S., Iiritano, E. and Parodi, A.( 2004) A 10-day levofloxacin-based therapy in patients with resistant Helicobacter pylori infection: a controlled trial. Clin Gastroenterol Hepatol;2:997-1002. 131/Shohreh, F. ,Abdolvahab, A., Aziz, Japoni,,M. H., Mehadi, S. F., Kamran, B.L., Ali, R. T., Jalil, N., Noreddin, R., Gholam, R. I.(2006). Immunodominant Antigens of Helicobacter pylori strains isolated from patients with different gastroduodenal diseases. Saudi Med J.;27.(6):794-803. 132/ Thomas, J.E., Gibson, G.R., Darboe, M.K., Dale, A., Weaver, L.T., Isolation of Helicobacter pylori from human faeces. Lancet 1992 Nov 14; 340(8829):1194-1195. 133//Hazell, S.L., Mitchell, H.M., Hedges, M., Shi, X., Hu, P.J., Li, Y.Y., Lee, A., Reiss-Levy, E., Hepatitis A and evidence against the community dissemination of Helicobacter pylori via feces. Journal of Infectious Diseases 1994 Sep; 170(3): 686-689 134/ Mitchell, H.M., Li, Y.Y., Hu, P.J., Liu, Q., Chen, M., Du, G.G., Wang, Z.J., Lee, A.and Hazell, S.L.( 1992) Epidemiology of Helicobacter pylori in southern China: identification of early childhood as the critical period of acquisition. Journal of Infectious Diseases; 166 (1): 149-153. 135/ Lambert, J.R., Lin, S.K., Sievert, W., Nicholson, L., Schembri, M., Guest, C., High prevalence of Helicobacter pylori antibodies in an institutionalized population: evidence for person-to-person transmission. American Journal of Gastroenterology Dec; 1995 90(12): 2167-2171 70 136/ Mendall, M.A., Goggin, P.M., Molineaux, N., Levy, J., Toosy, T., Strachan, D., Northfield, T.C.( 1992).Childhood living conditions and Helicobacter seropositivity in adult life. Lancet; 339 (8798): 896-897. 137/ McCallion, W.A., Murray, L.J., Bailie, A.G., Dalzell, A.M., O´Reilly, D.P.and Bamford, K.B.(1996) Helicobacter pylori infection in children: relation with current household living conditions. Gut J; 39 (1):18-21 138/ Vincent, P., Gottrand, F., Pernes, P., Husson, M. O., Lecomte-Houcke, M., Turck, D.amd Leclerc, H.(1994) High prevalence of Helicobacter pylori infection in cohabiting children. Epidemiology of a cluster, with special emphasis on molecular typing. Gut; 35(3):313-316 139/ Webb, P.M., Knight, T., Greaves, S.,Wilson, A., Newell, D.G., Elder J., Forman, D.(1994). Relation between infection with Helicobacter pylori and living conditions in childhood: evidence for person to person transmission in early life. BMJ/British Medical Association;19: 308(6931):750-753 140/ Rosenstock, S.J., Andersen, L.P., Rosenstock, C.V., Bonnevie, O.and Jorgensen, T.(1996) Socioeconomic factors in Helicobacter pylori infection among Danish adults. American Journal of Public Health; 86(11):1539-1544 . 141/ Megraud, F., Brassens-Rabbe, M.P., Denis, F., Belbouri A.and Hoa, D.Q.(1989). Seroepidemiology of Campylobacter pylori infection in various populations. Journal of Clinical Microbiology; 27(8):1870-1873 . 142/ Graham, D.Y., Adam, E., Reddy, G.T., Agarwal, J.P., Agarwal, R., Evans, D.J. Jr, Malaty, H.M. and Evans, D.G.(1991). Seroepidemiology of Helicobacter pylori infection in India. Comparison of developing and developed countries. Digestive Diseases and Sciences; 36 (8):1084-1088 . 143/ Seher, C., Thierfelder, W.and Dortschy, R.(2000). Helicobacter pylori--prevalence in the German population (Article in German). Gesundheitswesen; 62 (11):598-603 144/ Mohamed, A. M.. (2000). Antimicrobial agent, preparation of extract in :Biological activity of Nigella sativa.Thesis for PhD faculty of pharmacy university of Khartoum 145/ Guenther E.(1950). The essential oils Van Nostrand,New Yourk Vol.4 146/Lumir O.H.,Tomas, R.,Valery, M.and Dembitsky, A.. M.(2oo5) Myrrh-Commiplora . Chemistry. Piomed Papers;149.1:1-25 147/ Von Maydell, J. H.Trees and shrubs of the Sahel ,Their Characteristics and Uses . 148 / Marshall, Sarah ( 2004) Myrrh: magi, medicine and mortality. The pharmaceutical journa;l 18/25 Des 273: 919 -921 149/Greene; D., Gold, A. (1993). Frankincense.,myrrh and medicine. North Carolina Medical Journal;54:620-622 150/ Evansv, W.C.( 2002)Ttrease and Evans Pharmacognosy. .london WB Saunders; 15th ed. 71 151/Barnes, J., Anderson, L.A.and,Pillipson, J.D.(2002).Herbal medicines..Pharmaceutical Press2nd ed London 152/ /Gallo, R., Rivara, G., Cattrini, G. ,Cozzani, E.and Guarrera, M.( 1999) Allergic contact dermatitis from myrrh . contact dermatitis; 41: 230 – 231. 153//Wake, M., Hesketh, K., Lucas, J. (2000) Teething and tooth eruption in infants .A cohort study pediatrics;106:1374 – 1379 . 154/ Fenwic, A., Savioli, L. Engel, D. Bergquidt, N.R., Todd MH.(2003) Drugs for the control of parasitic disease :current status and development in Schistosomiasis Trends in parasitology ;19:509 5 155/ Michie, C. A,,and Cooper, E.(1991) Frankinicise and myrrh as remedieds in children . Journal of the Royal Socity of medicine ;84:602-605 156/ Malfertheiner, P. Stanesca, A.andSchultze, H.S.( 1988). Cmpylobacter urease test in diagnosis of chronic gastritis Acta Ther ;14:205-214 157 Cheersbor, M.(2000) ,Medical laboratory manual for tropical countries low price edition 7.5 biochemical test to identify bacteria 62-69. 158/ Chaves, M. S., Gadanho, R. T. and Jose, C. (1999). Assessment of Metronidazole Susceptiblity in H. pylori :Statistical Validation and Error Rate Analysis of Breakpoints Determied by the Disk Diffusion test American Society for Microbiology.Jan. 159/ Hartzen, S.H., Andersen, A., Bremmelgaard, H., Colding, M., Arpi, J., Kristiansen, T.,Justesen, F., Espersen, N., Frimodt-Moller, and O.(1997) .Bonnevie.Antimicrobial susceptibility testing of 230 H. pylori strains:importance of medium,lncoculum,and lncubation time.Antimicrob.Agens Chemother. ;41:2634-2639. 160/ Berger, S. A., Gorea, A.., M.oskowitz, M. Santo ,and Gilat, T.(1993).Effect of inoculums size on antimicrobial susceptibility of Helicobacter pylori. Eur. J. clin.Microbiol.Infect.;12:782-783 . 161/ NCCLS MIC Testing Supplemental Tables M 100-S13 (M7) January 2003 72 162/ Cheersbor, M. (2000) ,Medical laboratory manual for tropical countries low price edition 7.16 Antimicrobial sensitivity test 132-143 163/ Fedail.,S.S,Arbab, B. M., Homeda, M.M.Gandour .M 1983/ Upper gastrointestinal fibroptic endoscopy experience in Sudan :Analysis of 2500 endoscopy Lancet oct;.15;2:997-999. 164/ Dove Mp ,Graham Dy, seput veeda PBP-D 19998 .Involved in Amoxycillin resistance in H .pylori(Abastr).Gastroenterology 114;A109 165/ Wu, H., Shi,X.D., Wang H.T. and.Liu, J.X .( 2000). Resistance of Helicobacter pylori to metronidazole,tetracycline and amoxicillin .Journal of Antinecrobial Chemotherapy (JAC);46:121-123. 166/ Gunaid, A. A.,MBBS .MD. Hassan, A.N. and Murray –lyon ,I. (2003). Prevvalence and risk .facter for Helicobacter pylori infection among Yemeni dyspeptic patients. Saudi med J; vol 245: 512-517 167/ The EUOGAST study group (1993). Epidemioogy of, and risk factor for Helicobacter pylori infection among 3194 asymptomatic subjects in 17 populations .Gut ;34:1672-1676. 168/ Bekoe, E..L, (1999) . The changing sensitivity of Helicobacter pylori to Metronidazole . The Saudi Journal of Gastroenterology ;5,(3):124-128. 169/ Gilbou, S., Gaboug, G., Zamir, D., Zeer, A.and Novis, B. (1995) H. pylori infection in rural settlements in Israel. Int J. Epidemial;24 (1):386-392 170/ Adam, R. S , (2000). Biochemical identification of H. pylori and prevalence of resistance to Metronidazole in Sudan. Thesis for M. Sc degree Sudan University 171/ Thillianayagam, A. V., Arvind, A. S., Cook, R. S., Harrison, I.G.and Tabagchali, S. Farthing MTG. (1991) diagnostic efficiency of an ultrarapid endoscopy room test for Helicobacter pylori. Gut;32:467-469 172/ Miller,N.H., Sathar, M. A., Noran, A.D., Von den, E. J., SimJee, A.E. and Manion, G. (1991). Evaluation of various laboratory techniques to diagnosis Helicobacter pylori in patients with upper intestinal tract symptoms Afr med J ;80(11-12) :575-578. 73 173/ Marshall, B.J., Warren, J.R., Francis, G.L., Langton, S. R., Goodwin, C.S., and Blincow, E. (1987). Rapid urease test in the manegment of Campylobacter pyloridis-associated gastritis. Am.J.Gastroenterol ;82(3) :200-210. 174/ Glupczynslo,Y., Burette, A., Koster, E., Jean-Francois, N., Deltener, M., Candrame, S.,Bourdeaux, L.and Vos, D. (1993). Metronidazole resistance in H. Pylori . lancet ;335: 976-977. 175/ Banatvala, N., Davies, G.R., Abdi, Y., Clements, L., Rampttion, D.S., Hardie, J.M.and Feldaman RA.(1994). High prevalence of H. pylori Metronidazole resistance in migrants to east London :relation with previous nitroimidazole exposure and gastrodudenal disease. Gut ;35:1562-1566. 176/ Weil, J., Bell, G.D., Powell, K., Jobsson, R., Trowell, J.E., Gant, P.and Jones PH. (1990). H. pylori and Metronidazole resistance . Lancet ;336:1445. 177/ Queirosm, M.D., Combra, R.S. and Mendes,. (1993). Metronidazole resistant H, pylori in adeveloping country. Am. J Gastroentrol.;88:322. 178/ Teo, E K., Fock, K. M., Ng, T. M.,Khor, C.J.and Tan, A. (2000)Helicobacter pylori infection: Metronidazole resistant Helicobacter pylori in an urban asian populatin. J .Gastroentrol Hepaatol.; 15,5:4947- 49 179/ Tadashi, Sh., Shinsaku, F., Tatsuya, M., Michio, F., and Akihiro M. (2004). Efficacy of metronidazole for the treatment of clarithromycin-resistant Helicobacter pylori infection in a Japanese population J Gastroenterol ; 39:927–930 . 180/ Al.Qurashi, A.R., El Morsy, F. and Al.Quorain, A.A.( 2001). Evolution of Metronidazole and tetracycline susceptibility pattern in Helicobacter pylori at ahosiptal in Saudi Arabia. antimicrobial Agents;17,3:233-236. 181/ Bindayna, K.M.( 2001). Antibiotic susceptibility of Helicobacter pylori. Saudi Med J;22,1:5357. 182/ Becx, C J. M, Janssen, A., Clasener, and De koning, R.W. (1990). Metronidazole resistant H, pylori Lancet ;335:539-540. 183/ McMahon, B.J, Hennessy, T.W., Bensler, J.M, Bruden, D.L., Parkinson, A.J., Morris, J.M., 74 Reasonover, A.L ,Hurlburt, D.A, Bruce, M.G., Sacco, F. and.Butler, J.C. (2003) The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections. Ann Intern Med;139:463-469. 1184/ Megraud, F. (2004) H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut;53:1374-1384 185/ / Hua, J.S., Bow, H., Zheng, P.Y. and Khay-Guan, Y (2000). Prevalence of primary Helicobacter pylori resistance to metronidazole and clarithromycin in Singapore World Journal ; 6(1):119-121 186/ Adamek, R.J., Wegener, M.., Labenz, J.., Freitag., M., Opferkuch, W. and Ruhl, G.H. Mediumterm results of oral and intravenous omeprazole/amoxicillin Helicobacter pylori eradication therapy. Am J Gastroenterol 1994;89:39-42. 187/ Gasbarrini, A.V., Ojetti, A., Armuzzi, G., Brancaa, F., Canducci, E. Sanz, T.,Orre, M., Candelli, A.,Pastorelli, M. Anti, G., Fedeli, G., Faddaa, P. P and Gasbarrini, G.( 2000). Effcacy of a multistep strategy for Helicobacter pylori eradication. Aliment Pharmacol Ther ; 14: 79±83. 188/ Meyer, J.M., Silliman, N.P., Wang, W., Siepman, N.Y., Sugg, J.E., Morris, D., Zhang, J., Bhattacharyya, H., King, E.C.and Hopkins, R.J.(2002). Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993-1999. Ann Intern Med; 136: 13-24. 189/ Duck, W.M., Sobel, J., Pruckler, J.M., Song, Q., Swerdlow, D., Friedman, C., Sulka, A., Swaminathan, B., Taylor, T., Hoekstra M., Griffin, P., Smoot, D., Peek, R., Metz, D.C., Bloom, P.B., Goldschmidt, S., Parsonnet, J., Triadafilopoulos,G, Perez-Perez, G.I., Vakil, N., Ernst, P., Czinn, S., Dunne, D.snd Gold, B,D. (2004) Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States. Emerg Infect Dis;10:1088-1094. 190/ Dharmalingam, U.A., Rao, G Jayaraman, S.P.and Thyagarajan (2003). Relationship of plasmid profile with the antibiotic sensitivity pattern of Helicobacter pylori isolates from peptic ulcer patients in chennai. Indian Journal of Medical Microbiology, 21 (4):257-261. 191/Kagya, H. M., Kato, Y. Komatsu, T. Mizushima, M., Sukegawa, K., Nishikawa,K., Hokari, H., Takeda, T., Sugiyama, and Asaka, M..(2000). High-dose ecabet sodium improves the eradication rate of Helicobacterpylori in dual therapy with lansoprazole and amoxicillin. Aliment Pharmacol Ther; 14: 1523±1527. 192/ Dore MP, Piana A, Carta M,.(1998). Amoxicillin resistance is onereason for failure of amoxicillin±omeprazole treatment ofHelicobacter pylori infection. Aliment Pharmacol Ther;12: 635±9. 193/ Wu, X.H., Shi, H. T., Wang, and liu, .X.L. (2000). Resistance of H. Pylori to etronidazole, tetracycline and amoxycillin . Anti microbial chemotherapy ; 46: 121-123. 75 194/ Midolo, P. D, Korman. M.G., Turnidge, J. D., Lumbert, J.R. (1996).H. pylori resistance to tetracycline .Lancet ;347:1194-1195. 195/ Piccolomini, R., Bonaventura, G.D., Catamo, G., carboone , F. and Neri, M. (1997). Comparative evaluation of the E test , agar dilution and broth microdilution for testing susceptibilities of H. pylori strain to 20 antimicrobial agents. Journal of clinical Microbiology ;135:1842- 1846 . 196/ Roland, N.N., Alertia, E., Malange, T., Juliet, E. A., Ojongokpoko, H.N., Luma, A. Malongue, Jane-Francis, T.K., Akoachere, , Ndip, M. L., Martin, Mc and Lawrence, T. Weaver.(2008) .Helicobacter pylori isolates recovered from gastric biopsies of patients with gastro-duodenal pathologies in Cameroon: current status of antibiogram Tropical Medicine & International Health 13 ; (6) : 848 - 854 197/ O’Mahony,R.,Al-Khtheeri, H., Weerasekera, D., Fernando, N., Vaira, D., Holton, J.and Christelle Basset (2005). Bactericidal and anti-adhesive properties of culinary and medicinal plants against Helicobacter pylori . World J Gastroenterol ;11(47):7499-7507. 198/ Basset, C., Holton, J., O’Mahony, R.and Roitt, I.( 2003). Innate immunity and pathogen-host interaction.; 21 (l 2): S12-S23. 199/ Al –Harbi, M.M., Qureshi, S., Raza, M., Ahmed, M.M. and Afzal M.Sh. (1997). Gastric antiulcer and cytoprotective effect of Commiphora molomol in rats. J Ethnopharmacol, 55(2):141150. 76